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PATHWAYS CONTRIBUTING TO DEVELOPMENT OF SPONTANEOUS 
MAMMARY TUMORS IN BALB/c-Trp53+/- MICE 
 
Mutation and loss of p53 function are common features among human breast 
cancers. We use BALB/c-Trp53+/- mice as a model to examine the sequence of events 
leading to mammary tumors. Mammary epithelium proliferation rates were similar in 
both BALB/c-Trp53+/- mice and wild type controls. Among the 28 mammary tumors 
collected from BALB/c-Trp53+/- mice, loss of heterozygosity for Trp53 was detected in 
more than 90% of invasive mammary tumors. Transplantation of Trp53+/- ductal 
hyperplasias indicated an association between loss of the wild type allele of Trp53 and 
progression to invasive carcinomas. Expression of biomarkers such as ERα, PR, 
Her2/Neu and activated Notch1 varied among the tumors suggesting that multiple 
oncogenic events collaborate with loss of p53 function. The majority of the tumors 
expressed both luminal and basal cytokeratins (59%). Gene expression analysis showed 
 viii 
ligands and receptors of stem cell related pathways, such as Notch and Wnt, were 
increased in the tumors. These results indicate that mammary tumors in BALB/c 
Trp53+/- mice might initiate from bipotent mammary progenitor cells.  
 
USING MAGNETIC NANOPARTICLES FOR CANCER THERMOTHERAPY  
 
Alternating magnetic field (AMF) heating of magnetic nanomaterials provides a 
promising method for executing therapeutic thermal treatment for cancer patients. In 
order to explore the potential of magnetic nanoparticles (MNPs) for hyperthermia 
treatment, we synthesized iron oxide MNPs with various passivation by citric acid, folate, 
trimethylamine carboxylic acid, or albumin. The albumin passivated MNP (MNP-A) 
surpassed other MNPs, showing efficient heating with very low inherent cytotoxicity. 
Confocal microscopy located MNP-A (FITC tagged) accumulation in both cell nucleus 
and cytosol after 24hr incubation with HeLa cells. The quantity of cell bound MNP-A 
(including internalized and cell membrane bound MNP-A) was positively associated with 
MNP-A concentration and incubation time with cells.  The MNP-A bound to cells was 
sufficient to increase the temperature in the cell pellet ∆7°C after 8min exposure to AMF. 
No significant temperature increase or cell death was detected in control groups. Our data 
demonstrate that MNP-A provides a selective tool for AMF-induced thermal treatment, 
as well as useful dosing information for future preclinical animal studies.  
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CHAPTER 1 
 
 
 
INTRODUCTION  
An estimated 192,370 new cases of invasive breast cancer and 62,280 new cases 
of in situ breast cancer are expected to occur among women in the US during 2009 (1). 
Excluding cancers of the skin, breast cancer is the most frequently diagnosed cancer in 
women. An estimated 40,610 breast cancer deaths are expected in 2009. Breast cancer 
ranks second as a cause of cancer death in women (after lung cancer). Death rates for 
breast cancer have steadily decreased in women at 2.0-3.2% per year since 1990. The 
improvement is largely due to progress in both earlier detection and improved treatment.  
The exact mechanism that drives the normal mammary gland towards malignancy 
is still not clear, but new molecular biology techniques are enabling us to have better 
understanding of breast tumor cell biology and its molecular genetics during the process 
of tumorigenesis. 
Multistep Model of Breast Cancer Progression 
There are many models of human breast cancer evolution. One of the most well-
established models, published by Wellings and Jensen over 30 years ago, proposed that 
the cellular origin of most breast cancers occurs in the normal terminal duct lobular unit 
(TDLU) and that there is an apparently continuous but nonobligatory progression from 
TDLUs to cancer through a series of increasingly abnormal stages over long periods of 
time (2;3) (Figure 1.1). The key stages in this progression are called atypical ductal 
hyperplasia (ADH), ductal carcinoma in situ (DCIS), and invasive breast cancer (IBC) in 
today’s terminology (4). This model was originally based on the evidence of gradual 
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histological continuity. Confirmatory evidence that precursors and preinvasive lesions are 
clonal processes arises from studies showing similar genetic changes in low-grade DCIS 
and ADH and the shared genetic alterations between the precursors and IBC from the 
same patients (5-9). 
 
Figure 1.1 Multi-step model of breast cancer progression. 
Adapted from (4) 
 
On this spectrum, the diversity of histological features largely expands from 
premalignant lesions to malignancy. ADHs usually show quite well-differentiated 
histological and biological features, whereas IBCs show enormous diversity, ranging 
from very well to very poorly differentiated. DCIS reside between these extremes and are 
divided into three (e.g., low versus intermediate versus high grade) categories reflecting 
variations in the degree of differentiation (10). 
Changes in the expression of molecular markers also accompany the pathological 
change.  In the normal pre-menopausal breast, estrogen receptor positive (ER+) cells are 
luminal epithelial cells, evenly distributed and comprise 7% of the total epithelial cell 
population (11). ER positivity and proliferation (Ki67+) are almost mutually exclusive in 
normal epithelial breast tissue. It is thought that ER(+) cells secrete paracrine factors that 
influence proliferation of the adjacent ER(-) cells (12).  In ADH and DCIS, contrary to 
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the normal breast, ER(+) cells are surrounded by contiguous cells that are also ER(+). 
Moreover, ER(+)/Ki-67(+) cells are commonly seen in DCIS (12-14). In general, ER (+) 
IBC exhibit more frequent ER positivity in the tumor (15). On the other hand, there are 
approximately 35-60% of primary breast cancer are ER negative.  
Similar to estrogen receptors, progesterone receptors (PR) have been found 
elevated very early in premalignant breast lesions (16). In DCIS and IBC, PR positivity is 
usually associated with ER positivity (17;18). 
The Her2/Neu oncogene encodes a transmembrane tyrosine kinase receptor with 
extensive homology to the epidermal growth factor receptor (19). It is commonly 
overexpressed/amplified in human breast cancer. According to a variety of studies, 
Her2/Neu has not been found overexpressed at the protein level in benign proliferative 
breast disease or ADH (20-22). However, amplification of Her2/Neu has been 
documented with the use of fluorescent in situ hybridization (FISH) in ADH (21). In 
DCIS, Her2/Neu overexpression has been primarily associated with DCIS of higher 
grade, with (23) or without (24) IBC present. Approximately 30% of IBC has Her2/Neu 
overexpression/amplification (25).  
It is important to point out that deregulated expression of ER, PR, and Her2/Neu 
are not only the oncogenic driving force, but also therapeutic targets for hormone therapy 
or anti-Her2/neu monoclonal antibody therapy (1).  
Recently, comprehensive gene expression profiling of large sets of tumors by 
multiple independent groups and technologies have revealed five major molecular 
subtypes of breast cancer: luminal A, luminal B, Her2/Neu overexpressing, basal-like, 
and normal-like (26;27). The molecular differences result in distinct clinical outcomes 
 4 
and responses to treatment: the basal-like breast cancers have the worst outcomes, and 
within the estrogen receptor ER positive subtypes the luminal B cohort has a significantly 
worse prognosis than luminal A. These five subtypes are already present in DCIS (28) 
Although these data provide invaluable information about molecular 
epidemiology in each stage of the human breast cancer, it is difficult to follow sequential   
molecular changes in human breast cancer. Spontaneous mammary tumors from 
genetically engineered mice provide a model to individually examine the sequence of 
phenotypic and genetic alterations during mammary tumorigenesis. 
Genetically Engineered Mouse Mammary Tumor Model 
The initial studies of mouse mammary tumors focused on searching for the cause 
of cancer in high mammary tumor strains. These studies eventually led to the discovery 
of mammary tumor virus (MMTV) (29).  Though the comparable virus has not been 
identified in human or other species, the study of MMTV put down the foundation of the 
genetically engineered mice (GEM) mammary tumor model. The first genetically 
engineered mouse mammary tumor model used MMTV-LTR to promote Myc gene 
expression in the mouse mammary gland (30). These mice developed mammary tumors 
with a very short latency. Soon, transgenic mice with other oncogenes were created (31-
33). In addition to transgenic mice, conditional knockout mice from which the gene of 
interest (e.g. BRCA1 or Trp53) was removed from most cells in mammary gland, were 
generated for studying mammary tumor biology (34;35). Today, there are probably more 
than 100 GEM mammary tumor models covering almost all known tumor-related genes. 
Researchers use these models to study every aspect of tumor biology. Unlike MMTV 
induced tumors which are morphologically distinct from human breast cancer, many of 
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the mammary tumors in GEM mice mimic morphological features that resemble human 
breast cancers (36). In addition to morphological features, many of the defining 
molecular characteristics of human breast cancer subtypes (defined by gene expression 
profiling) were conserved among the GEM mouse models (37).  
Roles of Stem Cells in Cancer 
Among the five intrinsic subtypes of human breast cancer, basal-like breast 
cancers have drawn particular attention because they are associated with aggressive 
behavior, poor prognosis and typically do not express ER, PR or Her2/Neu ("triple-
negative"). Therefore, patients with basal-like cancers are unlikely to benefit from 
currently available targeted systemic therapy. This basal-like subtype of breast cancer 
preferentially overexpresses genes normally enriched in embryonic stem cells (38). In 
fact, many researchers support the hypothesis that breast cancer can initiate from stem 
cells (39).  
Embryonic stem cells have the potential to develop into all cell types in the body 
during early life and growth. Tissue specific stem cells remain in many adult tissues 
providing a reservoir for regeneration and repair of tissues, dividing when necessary to 
replenish dead cells. Stem cells account for a very tiny proportion of total adult tissue 
cells and may remain quiescent for long periods of time until they are recruited to fulfill 
the needs to maintain tissues due to normal turnover of cells or resulting from disease or 
tissue injury (40). 
The unique self-renewal feature shared between stem cells and cancer cells 
inspired an interesting hypothesis that cancer arises from stem cells (39;41;42). Many 
adult tissues are thought to be maintained by a hierarchical system in which a very small 
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population of self-renewing adult stem cells gives rise to proliferating progenitor cells 
that undergo limited rounds of mitotic division and then terminally differentiate, losing 
their ability to proliferate further. In this hierarchical system, only the stem cells are long-
lived (42). Malignant transformation comes from series of gene mutations which require 
long cellular life span or self-renewal ability to pass on the mutations. Fully differentiated 
tissue cells have short life spans and no ability to self-renew, whereas stem cells have 
long life span and large replicative potential which enable them to accumulate mutations 
over an extended period of time.  
Early evidence started with studies on acute myelogenous leukemia where 
leukemia initiating cells possessed characteristic features of normal primitive cells (43).  
Later research on non-hematopoietic systems discovered genes that are commonly found 
aberrantly expressed in tumor samples are also key players in stem cell regulation, such 
as genes involved in Wnt, Notch and Hedgehog pathways (44-46). MMTV-Wnt1 
mammary tissue harbors an increased number of stem cells and develops mammary 
tumors preferentially from these cells (47-49). Recently, Barker et al. used lineage tracing 
methods to directly demonstrate that colon crypt stem cells were the cellular target of 
transformation for intestinal cancer (50). In their study, deletion of Apc (adenomatous 
polyposis coli, negative regulator of Wnt pathway) in these stem cells leads to their 
transformation within days and they develop into adenomas within 3-5 weeks. 
Meanwhile, the same deletion in non-stem cell populations fails to drive malignant 
transformation (50).   
Parallel to the studies on the role of stem cells in tumorigenesis, a cancer stem cell 
concept prevails based on transplanted tumor formation tests from separate populations 
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of tumor cells. It postulates that a small reservoir of self-sustaining cells (cancer stem 
cells) are exclusively able to self-renew and give rise to the majority of tumor cells which 
are non-tumorigenic (51-56). Whether all cancer stem cells are transformed from normal 
tissue stem cells is still under debate, tumors initiate from stem cells do show the 
hierarchic cell organization (43). Analysis of tumors arising from transformed stem cells 
revealed that differentiation capacity of these cancer initiating stem cells is partially 
retained during tumor development (47-50). The aberrant differentiation, generating most 
of the cells within a tumor, most likely defines phenotypic features of each tumor.  
p53 Regulates Stem Cells 
Recently, p53 function has been linked to stem cells.  
p53 is a well know tumor suppressor gene. Mutation of the p53 tumor suppressor 
gene is one of the most common alterations identified in invasive tumors (57;58). The 
mechanisms by which p53 suppresses tumors are diverse. The roles of p53 in mediating 
cell cycle arrest and apoptosis have been described extensively (59). More recently, the 
activities of p53 have been expanded to include regulation of DNA repair, senescence, 
autophagy, cellular metabolism and microRNA processing (60-65). Overall, p53 is a 
central stress response protein that keeps the machinery of cell in control, preventing the 
proliferation of damaged cells which may ultimately leads to tumorigenesis (59). 
Recent evidence suggest p53 may affect how stem cells replicate in vivo. Tissue 
stem cells are usually quiescent. When needed, a stem cell can undergo asymmetric 
division, giving rise to one daughter stem cell (self-renewal) plus one cell that is destined 
to differentiate to normal tissue cells within a few divisions. In some cases, stem cells can 
execute symmetric division to generate two daughter stem cells, resulting in the 
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expansion of stem cell numbers (66). The p53 protein plays a fundamental role in 
restricting the pool of stem cells in embryonic stem cells (67-69) as well as adult tissues 
including hematopoietic system (70;71), neuronal system (72;73) and mammary gland 
(74;75). p53 null stem cells from mouse mammary glands undergo symmetric self-
renewal division (75%) in vitro while the WT control uses asymmetric division (80%). In 
vivo, the number of stem cells in mammary glands of p53 null mice was higher than WT 
controls and increased progressively over time (74). Recently, five different labs 
independently identified p53 as an important checkpoint during the multifactor 
reprogramming process in which induced pluripotent stem cells (iPS-cell) are derived 
from differentiated adult cells (76-80). In each case, inactivation of p53 enhanced the 
efficiency of iPS-cell production, suggesting p53 may be a major gatekeeper of self 
renewal function of stem cells. Overall, p53 is a key player in regulating stem cell 
replication, and loss of p53 function may result in abnormal expansion of the stem cell 
pool in normal tissue. 
p53 and Mammary Tumors 
Although disruption of p53 function predisposes the human body to a broad 
spectrum of malignancies, the breast epithelium appears exquisitely sensitive to proper 
p53 function. Polymorphisms in MDM2, CHK2 and ATM alter the stability and activity 
of p53 and have been linked to breast cancer risk in women. Breast cancer is the most 
prevalent tumor among women with Li-Fraumeni syndrome which is most commonly 
associated with heterozygous mutations in TP53 (81-83). In animal models, high 
incidence of mammary tumors develops after transplantation of p53 null mammary 
epithelium into fat pads of wild type mice (84) or somatic inactivation of p53 (35).  
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As p53 null mammary epithelium contains increasing numbers of stem cells and 
stem cells are potential targets to malignant transformation, tumorigenesis in the p53 null 
mammary epithelium may start with expanding the pool of putative tumor target cells. A 
few recent studies showed direct tumorigenesis from p53 deficient neutral 
stem/progenitor cells, osteoblast, and mesenchymal stem cells (85-87). These 
transformed stem cells (tumor initiating cells) partially retain their original differentiation 
in vitro and in vivo giving rise to the heterogeneous mass tumor cell population.  
As a Li-Fraumeni syndrome animal model, BALB/c-Trp53+/- female mice 
spontaneously develop a high incidence of mammary tumors (88;89). Compared to total 
function loss in p53 null mice, reduced dosage of the p53 gene has been associated with 
haploinsufficiency with respect to levels of p53 protein and activity, cell cycle arrest, 
apoptosis and homology-directed DNA repair (90-92). Recent investigation of 
astrocytomas further suggested that p53 heterozygous stem/progenitor cells display 
abnormal growth and differentiation properties in vitro before any gross morphological 
abnormality occurs (86). Therefore, the level of p53 activity appears to be a critical 
regulator of tumor suppressor pathways and breast cancer risk. 
The sequential changes occurring in normal tissue and in premalignant mammary 
lesions as a consequence of heterozygous mutations in TP53 would provide clues to the 
mechanisms that initiate the carcinogenic cascade as well as the cellular origins of breast 
cancer. While it is difficult to monitor sequential changes in human breast cancers, 
spontaneous mammary tumors of BALB/c-Trp53+/- female mice (89;93) provide a 
model to examine the sequence of phenotypic and genetic alterations during mammary 
tumorigenesis. 
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Role of p53 in Parity-Induced Protection from Breast Cancer  
Development of the mammary gland is tightly regulated by ovarian hormones 
throughout puberty and pregnancy. Mammary epithelium progresses through 
proliferation, differentiation, and regression as circulating levels of ovarian hormones 
change during the menstrual cycle and are most dramatic during pregnancy, lactation and 
involution.  Estrogens and progestins stimulate proliferation through their receptors on 
mammary epithelium and long term exposure to these hormones are associated with 
increased breast cancer risk (94). However, estrogens and progestins also mediate the 
protection from breast cancer afforded by parity. A full-term pregnancy early in 
reproductive life reduces breast cancer incidence by up to 50% (95).  
The activity of p53 has been shown to be responsive to hormones in rodent 
models (96-98). Exogenous estrogen and progesterone are sufficient to render the 
mammary epithelium resistant to carcinogen-induced tumors mimicking the protective 
effect afforded by a full-term pregnancy (99) and the p53 pathway participates in the 
hormone-induced protection by increasing p53 mediated apoptosis in mammary 
epithelium (84;100). 
Recent findings using mice have suggested that an early pregnancy (5 weeks) is 
associated with a small decrease in mammary stem cell number, although their capacity 
to repopulate the fat pad was unaffected (101). A later pregnancy (9 weeks) was shown to 
have no effect on the mammary stem cell pool (102). Further direct comparison is needed 
to provide convincing evidence regarding whether pregnancy protects via a persistent 
decrease in mammary stem cell activity (103). Considering the role of p53 in expanding 
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the stem cell pool, comparison between tumorigenesis in nulliparous and parous p53 
deficient mice may provide new supporting evidence on this issue. 
 12 
CHAPTER 2 
 
PATHWAYS CONTRIBUTING TO DEVELOPMENT OF SPONTANEOUS 
MAMMARY TUMORS IN BALB/c-Trp53+/- MICE 
Introduction 
Compromised function of the p53 tumor suppressor pathway remains among the 
most common alterations found in cancers (104). Although disruption of p53 function 
predisposes to a broad spectrum of malignancies, the breast epithelium appears 
exquisitely sensitive to proper p53 function. Polymorphisms in MDM2, CHK2 and ATM 
alter the stability and activity of p53 and have been linked to breast cancer risk in women. 
The activity of p53 has also been shown to be responsive to hormones in rodent models 
(105-107). Exogenous estrogen and progesterone are sufficient to render the mammary 
epithelium resistant to carcinogen-induced tumors mimicking the protective effect 
afforded by a full-term pregnancy (108) and the p53 pathway participates in the 
hormone-induced protection (84;109). Furthermore, breast cancer is the most prevalent 
tumor among women with Li-Fraumeni syndrome which is most commonly associated 
with heterozygous mutations in TP53 (110-112). Reduced dosage of the  p53 gene has 
been associated with haploinsufficiency with respect to levels of p53 protein and activity, 
cell cycle arrest, apoptosis and homology-directed DNA repair (90-92). Therefore, the 
level of p53 activity is a critical regulator of tumor suppressor pathways and breast cancer 
risk.  
The mechanisms by which p53 suppresses tumors are diverse. The roles of p53 in 
mediating cell cycle arrest and apoptosis have been described extensively (59). More 
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recently, the activities of p53 have been expanded to include regulation of DNA repair, 
senescence, autophagy, cellular metabolism and microRNA processing (60;64;113-116). 
Additionally, loss of p53 was shown to permit expansion of the pool of pluripotent 
embryonic stem cells (67;117) and cancer stem cells (117-119). The activities of p53 that 
are critical for suppression of tumors vary among tissues. In the thymus, the pro-
apoptotic activity of p53 was necessary to suppress lymphomas while the cell cycle 
checkpoint function was dispensable (120). In contrast, senescence is the principal 
pathway leading to regression of liver tumors following restoration of p53 function (121) 
and appears to be the prominent pathway in sarcomas as well (122). Among the known 
breast cancer susceptibility genes there is a convergence of function highlighting the 
central role of homology-directed repair of DNA double strand breaks in breast cancer 
risk (123).  Thus, fidelity of double strand break repair may be a critical pathway 
controlled by p53 in breast tissue.  
The sequential changes that occurring in normal tissue and in premalignant 
mammary lesions as a consequence of heterozygous mutations in TP53 provide clues to 
the mechanisms that initiate the carcinogenic cascade as well as the cellular origins of 
breast cancer. While it is difficult to monitor sequential changes in human breast cancers, 
spontaneous mammary tumors are common in BALB/c-Trp53+/- female mice (89;93) 
providing a model to examine the sequence of phenotypic and genetic alterations during 
mammary tumorigenesis. Using this model, we demonstrate that heterozygosity for 
Trp53 does not increase proliferation of the epithelium or the incidence of precancerous 
lesions. However, loss of the wild type allele of Trp53 was associated with the transition 
from hyperplastic to invasive phenotypes. In a set of 28 spontaneous tumors, histologic 
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phenotypes and expression of oncogenes were heterogeneous. The majority of tumors 
expressed markers of both luminal and basal epithelia (59%) suggesting that progenitor 
cells are the most common origin. However, significant numbers of tumors expressed 
purely luminal keratins (27%) or basal keratins (11%). Although distinct patterns of 
keratins were observed, stem cell markers were expressed similarly in tumors with only 
keratins associated with luminal cells (K8/18) as well as tumors expressing both luminal 
and basal cell keratins (K8/18 and K5/6). Therefore, it appears that tumors arise most 
frequently from progenitor cells which then commit toward more differentiated lineages 
during progression. Lineage decisions were not associated with specific activation of 
either Notch1 or Her2. As tumor phenotypes were stable after transplantation, this panel 
of tumors can be used to speed preclinical testing of chemotherapeutic agents.  
Material and Methods 
Mice 
BALB/c-Trp53+/- mice were generated, described previously (124), by 
backcrossing (C57BL/6 x 129/Sv) Trp53-/- mice onto the BALB/cMed strain for 11 
generations. Mice were genotyped by multiplex PCR as described previously (125). 
BALB/c-Trp53+/+ and Trp53+/- mice were monitored weekly for tumor development or 
morbidity, and were palpated for mammary tumors. 97 virgin female BALB/c-Trp53+/- 
mice and 30 Trp53+/+ mice, and 52 parous BALB/c-Trp53+/- mice were included in the 
study.  
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Estrous Stage Determination 
Stages of estrous were determined by cytological evaluation of vaginal smears. 
Vaginal smears of adult female nulliparous mice age 35-37 weeks were taken daily. Once 
the estrous stages were determined, mice were injected intraperitoneally with 30μg 5-
bromo-2-deoxyuridine (BrdU; Sigma, St. Louis, MO) per gram of body weight and 
sacrificed 2 hours later. Mammary glands were isolated and processed for 
immunohistological analysis. 
Mammary Gland Wholemount 
Mammary glands were removed and spread on glass slides and fixed in Carnoy’s 
fixative (60% ethanol, 30% chloroform, 10% glacial acetic acid) for 3 hours. The glands 
were washed in 70% ethanol for 15 minutes followed by brief rinse in distilled water. The 
tissues were then stained in carmine alum solution (1 gm carmine, 2.5 gm aluminum 
potassium sulfate/500 ml of water) at 4°C overnight. The tissues was dehydrated by 
soaking it in a series of solutions with increasing concentrations of ethanol (70-100%), 
washed in xylene twice, and mounted on a slide. 
Isolation and Culture of Transplantable Mammary Tumor Cells  
For transplantable tumor fragments: each mammary tumor from BALB/c-
Trp53+/- mice was minced and frozen in DMEM:F12 medium with 10%FBS, 7% DMSO 
following general cell freezing method and kept in liquid nitrogen. To isolate tumor cells, 
mammary tumors were removed from mice, rinsed in PBS, minced and incubated 3hrs at 
37ºC in medium containing DMEM:F12 supplemented with 25mM Hepes, 1.2g/L 
NaHCO3, 10µg/ml insulin, 5ng/ml EGF, 2% adult bovine serum(ABS), 100U/ml 
 16 
penicillin, 100µg/ml streptomycin, 0.25µg/ml amphotericin B and 0.2% collagenase type 
3 (Worthington 4182, 223U/mg). After dissociation and centrifugation, cells were grown 
in DMEM:F12 medium containing 2% ABS, 10µg/ml insulin, 5ng/ml EGF, 100u/ml 
penicillin, 100µg/ml streptomycin and 0.25µg/ml amphotericin B. The cells were 
expanded for 6 passages before freezing in liquid nitrogen.  
Transplantation of Mammary Hyperplasias, Tumor Fragments and Tumor Cell 
Lines  
Procedures for transplantation  of tissues into cleared mammary fat pads has been 
described previously (126). In brief, 21-24-day old BALB/c wild type females were used 
as transplant recipients. The endogenous mammary epithelium was surgically removed 
from the 4th inguinal glands to provide a cleared mammary fat pad. Fragments of PH1b 
and PH2 hyperplastic outgrowth lines (127) or spontaneous mammary tumors were 
inserted into the cleared mammary fat pads. Tumor cell lines were injected, 5x105 cells in 
10µL saline, into each cleared fat pad. Mice were palpated 3 times/week to monitor for 
tumor development. To test hormone dependence, tumor fragments were transplanted 
into recipients, then ovariectomized when tumors were palpable.  
Histology and Immunohistochemistry  
All collected tissues were fixed overnight at 4ºC in 10% neutral-buffered 
formalin, then stored in 70% ethanol until they were embedded in paraffin. Sections 
(4µm thick) were deparaffinized in xylene, then hydrated through a series of graded 
ethanol. The sections used for histopathological evaluation were stained with 
hematoxylin and eosin (H.E.). Immunohistochemical staining was performed using the 
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Dakocytomation Envision+System-HRP kit after antigen retrieval. The antibodies used 
were anti-ERα (1:200, MC 20, Santa Cruz Biotechnology), anti-PR (C-19, 1:50, Santa 
Cruz Biotechnology) and anti-mouse cytokeratin 6 (PRB-169P, 1:5000, Covance, 
Berkeley, CA, USA). BrdU staining was performed using BrdU staining kit (Zymed, 
Invitrogen, Carlsbad, CA). Immunofluorescence staining followed published procedures 
(37). Briefly, hydrated slides were boiled in sodium citrate (10mM) for 15min. After the 
slides cooled, they were incubated in blocking buffer (5%BSA/0.5%Tween-20 in PBS) 
for 1hr at room temperature. Then the slides were incubated in primary antibodies, anti-
cytokeratin 5 (1:8000, PRB-160P, Covance, Berkeley, CA, USA) and anti-Cytokeratin 
8/18 (1:400, GP11, Progen Biotechnick, Heidelberg, Germany) in a humid chamber at 
room temperature overnight. After series of washing steps, Texas Red® or CyTM2 
conjugated secondary antibodies (1:200, Jackson ImmunoResearch Laboratories, West 
Grove, PA) and DAPI (1μg/ml Sigma, St. Louis, MO) were added to the samples for 1hr 
at room temperature. Slides were mounted in mounting medium (2.5% Dabco/ 50mM 
Tris-HCl pH8.0/ 90% glycerol) and sealed with clear nail polish. 
Trp53 Genotyping and Loss of Heterozygosity 
Loss of heterozygosity (LOH) at Trp53 in hyperplastic outgrowths and tumors 
was determined by Southern blotting as described previously (88). The epithelium in 
hyperplastic outgrowths (PH1b, PH2) was enriched by digestion in DMEM:F12 
supplemented with 25mM Hepes, 1.2g/L NaHCO3, 10µg/ml insulin, 5ng/ml EGF, 2% 
adult bovine serum(ABS), 100U/ml penicillin, 100µg/ml streptomycin, 0.25µg/ml 
amphotericin B and 0.2% collagenase type 3 (Worthington 4182, 223U/mg) as described 
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for cell lines followed by centrifugation. Genomic DNA was extracted from the enriched 
epithelial pellet. For tumors, DNA was extracted directly from frozen tissue. Genomic 
DNA was digested with StuI and EcoR1. Southern blots were hybridized with a probe 
spanning exons 7-9 of the Trp53 gene. The intensity of the wild-type and null bands was 
quantified using a phosphorimager (Cyclone; Packard Bioscience, Boston MA) and the 
OptiQuant software package. The ratios of wild-type:null band hybridization values were 
calculated. Loss of the wild-type allele was defined as the ratio of wild-type:null alleles 
<0.5.  
Western Blot 
Flash-frozen tissues were homogenized in buffer (50mM Tris, 150mM NaCl, 1% 
TritonX-100, 1mM sodium vanadate, 10mM sodium fluoride, 10mM β-glycerol 
phosphate, 1x protease inhibitor from Sigma P8340) using 200 µl buffer/50 mg tissue. 
The protein concentration was determined using BCA reagent (Pierce, Rockford, IL, 
USA). Lysates (50 µg) were separated by 6% gel electrophoresis and electrophoretically 
transferred to nitrocellulose membrane. The membrane was incubated with anti-
Her2/Neu (1:250 C20, Santa Cruz Biotechnology), anti-Phospho Her2/Neu (Tyr1248, 
1:1000, Stressgen), anti-Notch1 (mN1A, 1:1000, eBioscience) or anti-β-actin (1:1000, 
Sigma A3853), followed by incubation with horseradish peroxidase conjugated 
secondary antibodies, and developed using an enhanced chemiluminescence (ECL) 
solution (Amersham, GE Healthcare UK, Buckinghamshire, United Kingdom).  
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Isolation of Mammary Gland Organoids 
Isolation of mammary gland organoids (enrichment of epithelium cells) was 
performed essentially as previously described (128). Briefly, mammary glands were 
removed from mice, rinsed in PBS, minced and incubated on a shaker for 1hr at 37ºC in 
medium containing DMEM:F12 supplemented with 25mM Hepes, 1.2g/L NaHCO3, 5% 
fetal bovine serum(ABS), 100u/ml penicillin, 100µg/ml streptomycin, 2mg/ml 
collagenase type 3 (Worthington 4182, 223U/mg), and 100U/ml hyaluronidase (Sigma 
H3506). Following enzyme digestion the fat layer was decanted and the remaining 
organoids were centrifuged and washed three times with PBS. The organoid pellets were 
subject to RNA extraction immediately after the washes. 
RNA Isolation and PCR Array Analysis 
Total RNA from mammary gland organoid and tumor samples were extracted by 
Qiazol Lysis Reagent (Qiagen, CA) and further purified using Qiagen RNeasy Mini Kit 
(Qiagen, CA). PCR array analysis was performed by using 1µg of total RNA of each 
sample and the RT² Profiler™ PCR Array for mouse stem cells (SABiosciences, 
Frederick, MD) according to the recommendations of the manufacturer. Expression levels 
on each array plate were normalized using two housekeeping genes: Hprt1 and 
Hsp90ab1. Tumor samples were compared to mammary gland organoids from age 
matched BALB/c-Trp53+/- mice. Analysis of ∆Ct and fold changes was conducted using 
the online data analysis tool supported by the array manufacturer. Genes were considered 
to be differentially expressed if the fold-change between tumor and mammary epithelial 
organoids was >2.5. Genes that are differentially expressed between the “mixed keratin” 
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tumors (V06, V22) and “luminal keratin” tumors (V07, V14) were selected if the ratio 
differed by >4-fold. 
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Results §
Analysis of Preneoplastic Changes in BALB/c-Trp53+/- Mammary Tissues 
 
Previously, Kuperwasser C. etc from our lab has developed a mammary tumor 
model in BALB/c Trp53+/- mice (89). In order to further dissect the role of p53 and 
examine the sequential events during mammary tumorigenesis, tissues were collected 
from BALB/c-Trp53+/+ and BALB/c-Trp53+/- nulliparous female mice at 8 week 
intervals up to 52 weeks.  The overall ductal structure showed no difference in branching 
or alveologenesis between the two groups (Figure 2.1A). Proliferation rates were also 
similar for both genotypes at 36wks (Figure 2.1B). Sporadic hyperplastic foci were seen 
in BALB/c-Trp53+/- mice (Figure 2.1C), but the incidence was too low to compare 
between the groups. Thus, heterozygosity for Trp53 did not increase proliferation or 
appearance of precancerous lesions.  
                                               
§ Most of the data in this chapter is published in American Journal of Pathology, 
2010 Mar;176(3):1421-32 
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Figure 2.1 Mammary gland morphology in BALB/c-Trp53+/+ and -Trp53+/- mice.  
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(A) Wholemount and H&E staining of mammary glands from 20-52wk-old mice. (B) 
Proliferation of mammary epithelial cells was determined at different estrous phases by 
BrdU incorporation. The histogram shows the average percentage of BrdU positive cells. 
No significance was detected between the Trp53 genotypes in either stage. At least 2500 
epithelial cells were counted per slide for a minimum of three mice per genotype. (C) 
Hyperplastic foci appeared at low incidence in wholemounts (left) and H.E (right) from 
Trp53+/- mice. Scale bars: 1mm in wholemounts; 40µm in H.E; 20µm in BrdU staining. 
 
 
 
Loss of heterozygosity (LOH) for Trp53 is observed frequently in breast cancers 
and was also observed in 90% of spontaneous mammary tumors from BALB/c-Trp53+/- 
mice (88). In this panel, well-differentiated lesions such as mammary intraepithelial 
neoplasias (MIN) retained the wild type allele of Trp53, while poorly differentiated 
adenocarcinomas had near complete LOH (Figure 2.2A). To explore the timing of Trp53 
LOH, two transplantable hyperplastic lines (PH1b & PH2) derived from BALB/c-
Trp53+/- mice (127) were transplanted into cleared mammary fat pads in BALB/c-
Trp53+/+ hosts. The PH outgrowths displayed abnormal ductal morphologies in the 
recipient glands and later developed into invasive carcinomas with latencies of 16-26 
weeks. Despite the Trp53 heterozygous status of the PH lines, 8/9 of the resulting tumors 
lost the wild type allele of Trp53 (Figure 2.2B). These results suggested that complete 
loss of Trp53 is not necessary to establish premalignant lesions such as hyperplasias or 
mammary intraepithelial neoplasias (MIN), but LOH is strongly associated with the 
transition into invasive tumor. 
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Figure 2.2 Loss of heterozygosity during mammary tumorigenesis in BALB/c-
Trp53+/- mice. 
The proportions of wild type (WT) and null (Null) alleles in tumors were determined by 
Southern blot hybridization and were compared with the ratios for tail DNAs from mice 
that were homozygous for the wild type allele or heterozygous (Trp53+/+ and Trp53+/-, 
respectively). Reductions in the WT allele below 50% (indicated by the dashed line) were 
considered significant loss of heterozygosity. (A) The majority of tumors showed loss of 
wild-type allele.  (B) The transplanted ductal hyperplasias (PH1b, PH2) used for 
transplantation retained the WT allele at levels equivalent to tail DNA controls. However, 
tumors developing from the hyperplasias showed severe loss of heterozygosity in all 
cases except MT6577. 
 
 
A. 
B. 
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Pathological and Genetic Alterations Associated with BALB/c-Trp53+/- Mammary 
Tumors  
We next explored whether mammary tumorigenesis in BALB/c-Trp53+/- mice 
follows a restricted set of pathological or molecular pathways. The histological features 
of the total 28 spontaneous mammary lesions collected ranged from intraepithelial 
neoplasia to invasive carcinomas (Figure 2.3). As collections were focused on large 
palpable lesions, the majority of tumors were poorly differentiated invasive ductal 
adenocarcinomas. A minority of tumors (2/28) underwent transdifferentiation into 
adenosquamous carcinoma or had focal squamous differentiation. A complete summary 
of tumor characteristics is provided in Table 2.1. 
 
 
 
Figure 2.3 Histological characterization of BALB/c-Trp53+/- mammary lesions. 
Mammary lesions from BALB/c-Trp53+/- mice showed diverse histological features 
including (A) intra-epithelial neoplasia (MIN, V05), (B) ductal adenocarcinoma (V03), 
(C) adenocarcinoma with acinar morphology (V23), (D) adenocarcinoma with squamous 
differentiation (V01), (E) carcinosarcoma (V08), (F) solid sheets of tumors with little 
stroma (V26), (G) adenocarcinoma with strong stromal reaction (V13) and (H) 
adenocarcinoma with spindle cell feature (V28). Scale bar: 20µm. 
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Table 2.1 Features of mammary tumors from nulliparous BALB/c-Trp53+/- mice. 
Sample Tumor Type Latency (weeks) 
LOH 
WT/Null PR ER 
Her2
/neu 
K8/
18 K5 K6 Met
∆ 
V01 adenocarcinoma 30 12.6 - - - - + + - 
V02 adenocarcinoma 30 lost null signal - - - + + + - 
V03 adenocarcinoma 40.7 5.9 + + - + + +  
V04 adenocarcinoma 46.7 8.8 - - - + + +  
V05 MIN* 47.1 64.9 + + - + + +  
V06 adenocarcinoma 46.3 1.4 - - - + + + - 
V07 adenocarcinoma 48.9 7.7 - -  + - - + 
V08 carcinosarcoma 49.1  - -  + + +  
V09 adenocarcinoma 42 10.2 + + - + + + - 
V10 adenocarcinoma 42 4.5 - - +++ + + +  
V11 adenocarcinoma 53.9 46 - -  + - -  
V12 adenocarcinoma 53.9 28.2 + +      
V13 adenocarcinoma 52  - -  - + +  
V14 adenocarcinoma 39.7 8.2 - - +++ + - - - 
V15 adenocarcinoma 50.4 54.8 - - - + - -  
V16 adenocarcinoma 50.4  - -  + + +  
V17 adenocarcinoma 50.9 8.2 - - ++ + + +  
V18 adenocarcinoma 47.4 0 - - ++ + + +  
V19 adenosquamous carcinoma 50.1 28.6 - - - + + +  
V20 adenocarcinoma 52.9 40 - - + - + + + 
V21 adenocarcinoma 47.1 12.8 - - + + + +  
V22 adenocarcinoma 48.1 29.7 - - - + + +  
V23 adenocarcinoma 47.9 8.7 - - - + - -  
V24 adenocarcinoma 50.4 15.5 - - - - - +  
V25 adenosquamous carcinoma 48.6 34.1 - - ++ + + +  
V26 adenocarcinoma 40.7 7.4 - - ++ + - -  
V27 adenocarcinoma 49.1 44.7 - - - + + +  
V28 adenocarcinoma 48.7 29.7 - - - + - -  
* MIN: Mammary intraepithelial neoplasia;  ∆Met: Metastasis; N/A: Not available 
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Deregulation of estrogen receptor alpha (ERα) and progesterone receptor (PR) 
expression was observed during progression of the mammary gland lesions in BALB/c-
Trp53+/- mice. Individual ERα and PR positive cells are distributed in normal ducts 
throughout Trp53+/- mammary glands (Figure 2.4A-C). An increase in clusters of ERα 
and PR positive cells was detected in ductal hyperplasias from BALB/c-Trp53+/- mice 
(Figure 2.4D-F). Expression of ERα and PR was retained in the majority of early lesions 
(MIN; Figure 2.4G-I) but lost in most invasive carcinomas (Figure 2.4M-O). In this 
panel, 3 of 27 malignant tumors were ERα+/PR+ (Figure 2.4J-L). The expression of 
ovarian steroid receptors during tumorigenesis in BALB/c-Trp53+/- mammary tissues 
mimics the pattern during progression of human breast cancers (14).   
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Figure 2.4 Expression of ERα and PR in mammary tissues and tumors. 
Consecutive sections were stained with either H.E. or antibodies detecting estrogen 
receptor alpha or progesterone receptor. Pre-invasive lesions (Hyperplasias and MIN) 
retained expression of the steroid hormone receptors while the expression in tumors was 
variable. (A-C) Mammary duct;  (D-F) ductal hyperplasia; (G-I) mammary 
intraepithelial neoplasia (V05); (J-L) ERα+/PR+ mammary adenocarcinoma (V09); (M-
O) ERα-/PR- mammary adenocarcinoma (V13). Arrow head indicates entrapped 
mammary duct. Scale bar: 20µm. 
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Selected oncogenic alterations may collaborate with loss of p53 to stimulate 
progression of tumors in specific cellular compartments yielding tumors with distinct 
phenotypes. Her2/Neu expression was examined as it is commonly overexpressed in 
human breast cancers, often in conjunction with mutations in p53 (25). Similar to breast 
cancers, levels of Her2/Neu protein were elevated in 36% (8/22) of the BALB/c-Trp53+/- 
mammary tumors. The Her2/Neu protein appeared to be active as it was phosphorylated 
(Figure 2.5). Although protein levels were elevated, it was not associated with 
amplification of the Her2/Neu gene as determined by Southern blot (data not shown). 
Recent findings have suggested that p53 regulates Notch1 receptor activities, though the 
effect seems to differ among tissues (130;131). Activated Notch-1 expression was 
identified in BALB/c-Trp53+/- mammary tumors (Figure 2.5). Levels of activated 
Notch1 varied among BALB/c-Trp53+/- mammary tumors, but were independent of 
histopathological types or expression of other biomarkers. These results revealed the 
heterogeneous molecular alterations among mammary tumors from BALB/c-Trp53+/- 
mice. 
 
Figure 2.5 Expression of Her2/Neu and Notch1 oncogenes in mammary tumors. 
Western analysis using anti-Her2/Neu, anti-phospho-Her2/Neu (p-Her2/Neu) antibodies 
and antibody against intracellular domain of Notch1 were used to examine expression in 
tumors. Nulliparous mammary tissue (N) from Trp53+/- mice was used for comparison. 
Lysates from A431 cells and mice spleenocytes cells (stimulated with CD3 & CD28) 
were used as positive controls (P) for Her2/Neu and Notch1, respectively. 
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Mammary Tumor Fragment and Cell Line Banks from BALB/c-Trp53+/- Mice. 
Based on the 28 spontaneous mammary tumors from BALB/c Trp53+/- mice, we 
established a mouse tumor bank including transplantable tumor fragments from 20 
tumors and tumor cell lines from 10 tumors.   
Cryopreserved tumor fragment (barely visible by eye) can be transplanted into 
mammary fat pad of wild type BALB/c mice. Palpable tumors can be detected within 2-3 
weeks in most cases. The tumor outgrowths retained the histological features of the 
primary tumors. In the case of the V09 tumor, both primary tumor and outgrowths after 
transplantation expressed ERα (Figure 2.6A-D). However, the tumor transplants 
expressed ERα at levels greater than the endogenous epithelium, their growth was 
unaffected by ovariectomy (Figure 2.6E)  
The tumor fragment bank expanded the depth and possibility of our study on 
metastasis. Although all original mammary tumors exhibited highly invasive phenotypes, 
distant metastases were not detected during the observation period up to 14 months. The 
metastatic potential of these mammary tumors could be masked, as mice were sacrificed 
due to large mammary tumors or coincident lymphomas. To further address the 
metastatic potential of the mammary tumors, tumor fragments from 8 of the primary 
BALB/c-Trp53+/- mammary tumors (V01, V02, V06, V07, V09, V14, V20, V22) were 
transplanted into mammary fat pads that had been cleared of endogenous epithelium in 
BALB/c-Trp53+/+ hosts. The tumor outgrowths were resected to allow longer periods of 
observation. Two outgrowth lines, V07 (ERα-/PR-) and V20 (ERα-/PR-, Her2/Neu+), 
among the eight tested tumors formed metastases in the lungs (Figure 2.6F).  
 31 
 
Figure 2.6 Outgrowths from transplanted tumor fragments. 
ERα+ adenocarcinoma V09 (A,B) fragments were transplanted into mammary fat pads 
that had been cleared of endogenous epithelium in BALB/c-Trp53+/+ hosts. The tumor 
outgrowth in recipient BALB/c wild type mouse remained ERα+ adenocarcinoma (C,D). 
Half of the recipient mice were ovariectomized (OVX) when tumors were palpable. 
Tumor growth (E) was compared between ovary intact group and OVX group. Metastasis 
was seen in mice bearing transplants of tumor fragment from the V07 tumor (F). Scale 
bar: 20µm. 
 
 
Compared to outgrowth from tumor fragments, outgrowth from tumor cell 
injection resemble less of original tumor yet more homogenous structure (Figure 2.7). It 
might be due to the culture condition while cells were isolated from minced tumor 
samples. The culture conditions favors growth of epithelial cells, consequently stromal 
cells were selected against during cell passaging. Before stable tumor cell lines were 
established, each line had also endured massive cell death and senescence during the 
initial transition to 2D culture and the first few passages. When stable cell replication and 
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regular cell passaging were achieved on each line, the culture may consist of only a few 
clones of tumor cells from the original sample.  
 
Figure 2.7 Outgrowth of transplanted tumor fragments and tumor cells isolated 
from spontaneous tumor. 
Tumor fragments and cell line isolated from Adenocarcinoma V14 (A) were transplanted 
into mammary fat pads that had been cleared of endogenous epithelium in BALB/c-
Trp53+/+ hosts. (B) Outgrowth from V14 tumor fragment. (C) Outgrowth from V14 
tumor cell line. Scale bar: 20µm.  
 
 
Origins of Mammary Tumors 
To investigate the cellular origins, tumors from BALB/c-Trp53+/- mice were 
stained for markers of basal and luminal epithelial lineages (cytokeratins 5 or 8/18, 
respectively). A mixture of cells expressing either K5 or K8/18 (Figure 2.8A) was 
observed in 59% of the tumors, but co-expression of K5 and K8/18 in individual cells 
was rare. Both of the K5-positive cells and K8/18-positive cells were pleomorphic, 
disorganized, and in large quantities within each tumor. 26% of the tumors expressed 
only luminal cytokeratins (K8/18, Figure 2.8D) and 11% of the tumors expressed only 
K5-positive cells (Figure 2.8G). Tumors were also stained with cytokeratin 6 (K6) 
because it was found to be preferentially expressed in mammary stem/progenitor cells 
(132) and expanded in mammary tumors originating from progenitor cells (47;133;134). 
None of the K8/18-positive-only tumors contained K6 positive cells (Figure 2.8E-F), 
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whereas all of the double positive tumors and K5-positive tumors show K6 positive cells 
(Figure 2.8B-C, H-I). As the majority of tumors contained both luminal and basal cell 
lineages, it appears that tumors most often originate within the population of bipotent 
progenitors.  
 
Figure 2.8 Heterogeneous patterns of keratin expression in mammary tumors from 
BALB/c-Trp53+/- mice. 
Mammary ducts from BALB/c-Trp53+/- mice expressed cytokeratins normally with K5 
localized to the basal/myoepithelium and K8/18 restricted to the luminal epithelium. (A) 
Most of the mammary tumors express a mixture of cells expressing K8/18 (green) with 
K5 (red). Though both cell populations were similarly abundant, cells expressing both 
luminal and basal keratins were rare. A smaller number of tumors have only K8/18 
expressing cells (D) or only K5 expressing cells (G).  Serial sections were also stained for 
K6 confirming the expanded populations of cells with basal-like cytokeratins among 
tumors composed of mixed populations of cells (A, C) and tumors expressing only K5 
(G, I).  In contrast, K8/18-only expressing tumors contain no K6 expressing cells (A, C). 
Although basal-like tumors contained cells that were positive for K5 and K6, individual 
cells do not necessarily express both (see B vs C, H vs I). Scale bar: 20µm. 
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Stem cell-related genes were shown to be enriched in aggressive breast cancers 
and have been suggested to reflect the origins of cancers within the progenitor cells of the 
breast epithelium (38). Therefore, expression of a panel of 84 stem cell-related genes was 
profiled in tumors that expressed either mixed luminal and basal keratins (V06, V22) and 
tumors expressing only luminal keratins (V07, V14). Distinct differences were observed 
for 9 genes (Figure 2.9, upper panel). N-cadherin (Cdh2) was elevated 22-fold in the 
“mixed keratin tumors” compared to normal mammary epithelial organoids while the 
“luminal-only keratin tumors” showed a 4-fold decrease compared to the normal 
mammary epithelial organoids. Expression of Krt15 was also specifically elevated in the 
mixed keratin tumors along with cyclins D2 and E1 (Ccnd2, Ccne1). However, the 
overwhelming majority of genes showed similar patterns in both the tumors with mixed 
keratins as well as the tumors with luminal-only keratins (Figure 2.9, lower panel). While 
it is not surprising that both sets of tumors had elevations in proliferation-associated 
genes (Figure 2.9-I) compared to the normal mammary epithelium, levels of cytokines 
and growth factors were decreased (Figure 2.9-II). Both Notch and Wnt pathways have 
been implicated in maintenance of mammary stem cells (45;135;136). In both sets of 
tumors, ligands and receptors for Notch and Wnt were increased indicating that signaling 
through these pathways is increased dramatically compared to the normal mammary 
epithelium (Figure 2.9-V,VI). Therefore, there is broad overlap in the signaling pathways 
found in the tumors suggesting a common origin of the tumors regardless of the pattern 
of keratins expressed. 
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Figure 2.9 Expression of stem cell related genes in tumor samples differing in 
keratins expressed. 
Expression of stem cell related genes was examined in tumors expressing “mixed 
keratins” (V06, V22) and tumors with “luminal-only keratins” (V07, V14). The 
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expression of each gene is presented as a ratio compared to the levels in normal 
mammary epithelium obtained by enzymatic digestion. A set of 9 genes are differently 
expressed between the two groups (top panel). However, 69 genes showed similar 
patterns of expression between the groups (bottom panel). The genes are grouped 
according to functions or pathways. (I) Cell cycle regulators, chromosome modulators 
and cell division related genes; (II) Cytokines and growth factors; (III) Cell adhesion 
molecule; (IV) Embryonic stem cell related genes; (V) Notch pathway related genes; (VI) 
Wnt pathway related genes; (VII) Tissue specific stem cell markers.  
 
Parity is Protective in the BALB/c-Trp53+/- Mice 
Parity is protective against breast cancer in human (95). We tested the protective 
effects in BALB/c-Trp53+/- mice by comparing tumor incidences and latencies between 
nulliparous Trp53+/- group and parous Trp53+/- group. Mammary tumors occurred in 
43.2% of the nulliparous mice and 34.6% of the parous mice. Mammary tumor-free 
survival time was increased by 15 weeks in the parous group (Figure 2.10A, P < 0.0001) 
(90). So parity is effective in protecting from mammary tumors in this mouse model of 
Li-Fraumeni syndrome.  
A few markers were used to detect possible molecular difference between the 
tumor from nulliparous mice and parous mice. There is an increase of ER+ tumors from 
parous mice (5/22, Table 2.2) compared to nulliparous mice (3/27, Table 2.2). So far it is 
hard to explain the increased proportion of ER+ tumors from parous mice. Since 
BALB/c-Trp53+/- mammary tumors appear to progress from ER+ to ER-, one of the 
explanations could be the earlier stage tumor collection in parous mice (older) due to co-
morbidities (like lymphomas).   
We applied lineage specific cytokeratin stain to the tumors from BALB/c-
Trp53+/- parous mice (Figure 2.10). The majority of the parous tumors still contained a 
mixture of luminal (K8/18) and basal (K5) cytokeratin positive cells. Luminal (K8/18) 
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positive only tumors and basal (K5) positive only tumors were still proportionally in the 
minority. The fact that the proportion of each group of tumors (mixed, luminal or basal) 
remains similar between nulliparous and parous tumors supports the theory that parity 
protects against mammary tumors in BALB/c Trp53+/- mice by reducing the stem cell 
pool in those mice. 
 
 
Figure 2.10 Parity is protective against mammary tumors in BALB/c-Trp53+/- mice. 
(A) The incidence of mammary tumors was monitored in both nulliparous and parous 
BALB/c-Trp53+/- female mice. The latency of spontaneous mammary tumors was 
increased in parous compared with nulliparous mice (P < 0.001) (90). (B) Cytokeratin 
(K8/18, K5) stain were compared between tumors from nulliparous and parous BALB/c-
Trp53+/- female mice. Tumors contain mixed lineage cells dominant in both groups. There 
is a slight increase of luminal (K8/18) positive only tumors and a slight decrease of Basal 
(K5) positive only tumors in parous tumors compared to nulliparous ones. Tumor stained 
negative for both K8/18 and K5 was categorized as "Other". 
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Table 2.2 Features of mammary tumors from parous BALB/c-Trp53+/- mice. 
Sample Tumor type ER K8/18  K5  
P01 adenocarcinoma - + - 
P02 MIN* - + - 
P03 adenocarcinoma - + - 
P04 adenocarcinoma - + + 
P05 adenocarcinoma - + + 
P06 adenocarcinoma + + - 
P07 adenocarcinoma - + - 
P08 adenocarcinoma - + + 
P09 adenocarcinoma + + + 
P10 adenocarcinoma + + + 
P11 adenocarcinoma - + + 
P12 adenocarcinoma - + + 
P13 adenocarcinoma   + + 
P14 adenocarcinoma - + + 
P15 adenocarcinoma - + - 
P16 adenocarcinoma - + + 
P17 adenocarcinoma - + + 
P18 adenocarcinoma + + + 
P19 adenocarcinoma - + + 
P20 adenocarcinoma - + - 
P21 adenocarcinoma - + + 
P22 adenocarcinoma + + - 
P23 
adenosquamous 
carcinoma - - + 
P24 MIN + + + 
* MIN: Mammary intraepithelial neoplasia 
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Discussion 
Although the p53 tumor suppressor pathway is commonly disrupted in a variety 
of cancers, breast tissue appears to be uniquely sensitive to the proper functioning of this 
pathway to prevent tumors. Heritable mutations in the TP53 gene have been linked to Li-
Fraumeni syndrome and breast cancer is the most common tumor type in women (81;83). 
Somatic mutation of TP53 is also common in sporadic breast cancers (57;58) and may 
initiate tumorigenesis by pathways similar to those in Li-Fraumeni syndrome. Similar to 
Li-Fraumeni syndrome, BALB/c-Trp53+/- mice exhibit a prevalence of mammary tumors 
as well as lymphomas and sarcomas (89). The slow onset of mammary tumors allowed 
detailed analysis of the cellular targets and molecular events leading to mammary tumors. 
Although deficiency in p53 has been associated with impaired cell cycle control and 
apoptosis, there was no detectable difference in proliferation rates within the mammary 
epithelium of Trp53+/- and Trp53+/+ mice (Figure 2.1).  In contrast, both basal and 
radiation-induced apoptosis in the mammary epithelium were decreased with Trp53 gene 
dosage (90). Therefore, haploinsufficiency with respect to apoptosis, not proliferation, is 
associated with the susceptibility to mammary tumors in BALB/c-Trp53+/- mice. 
Haploinsufficiency in p53-mediated apoptosis has been observed in the involuting 
prostate of mice (137) and the pro-apoptotic role of p53 appears to be critical for 
suppression of lymphomas while cell cycle checkpoint function was dispensable (120). 
Thus, a decrease in p53 dosage was suggested to be sufficient to initiate breast tumors 
(138). However, in our study, the diminished spontaneous apoptosis in Trp53+/- 
mammary epithelium did not lead to a discernable increase in preneoplastic lesions 
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compared to the Trp53+/+ mice. The glands were normal with respect to ductal 
branching and alveologenesis. Therefore, Trp53 haploinsufficiency alone did not permit 
initiation of preneoplasia.  
Although TP53 LOH is frequently observed in breast tumors among Li-Fraumeni 
patients (139), it has been unclear whether loss of the wild type allele of TP53 initiates 
preneoplasia or it accompanies the transition to invasive cancers. In BALB/c-Trp53+/- 
mammary tissues, LOH was prevalent in invasive tumors, but not hyperplasia or MIN. 
Although rates of LOH in tumors differs between strains of mice and segregates with the 
predisposition to mammary tumors (88), LOH at Trp53 was also observed in K14-
cre,Trp53fl/+ mice in a mixed 129xFVB background (140). Therefore, LOH appears to be 
a rate-limiting step in the genesis of mammary tumors. As p53 plays an important role in 
responding to oncogenic stimuli and the DNA damage response (DDR), it has been 
proposed that p53 function limits growth of preneoplastic cells and loss is necessary for 
progression (141). These results favor a model of carcinogenesis in which activation of 
oncogenes stimulate preneoplasia in both Trp53+/- and Trp53+/+ tissues. Though 
progression is limited by p53, the pro-apoptotic activity and double strand break repair 
pathways are impaired in Trp53+/- tissues allowing illegitimate mitotic recombination 
(88) which can abolish the wild type allele of Trp53 eliminating the rate limiting step in 
the tumor progression.  
While the requirement for loss of p53 function appears uniform, the histological 
appearance of the tumors in p53-deficient mice suggests divergent cellular origins. 
Oncogene-specific tumor phenotypes have been reported in transgenic mice expressing 
Her2/Neu or Ras (33;36;142), and thus, the heterogeneity of the tumors may reflect the 
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collaborating oncogenes. Alternatively, the tumor phenotypes may depend on the cellular 
origins. Selective deletion of Trp53 in basal or luminal compartments using the Cre 
recombinase under control of K14, MMTV or WAP promoters resulted in heterogeneous 
tumor phenotypes (35;140;143) suggesting that tumors can arise from both luminal and 
basal cells.  However, the origins were not definitive as Cre activity was evident in both 
the luminal and basal cells in these experiments. A WAP-cre that is restricted to the 
luminal epithelium and is pregnancy-dependent to drive activation of a point-mutation of 
Trp53 (R270H) yielded tumors that were positive, as well as negative for ERα (144) 
suggesting that the luminal lineage can yield both ERα-positive and –negative tumors. 
Using more extensive immunophenotyping, we found that 59% of spontaneous mammary 
tumors in BALB/c-Trp53+/- mice expressed both luminal and basal keratins (K8/18 and 
either K5 or K6) suggesting origin of the tumors within bipotent progenitors (summarized 
in Figure 2.11). A smaller fraction of tumors expressed only luminal or basal keratins. 
There was no association between the oncogenes expressed and tumor phenotypes as 
Her2/Neu and Notch1 were detected in tumors with either luminal or basal keratins while 
the ERα-positive tumors were positive for both luminal and basal keratins. Although 
tu mor V0 9  exp resses h igh lev els of ERα and  PR and  the p henotype was stab le when  
tumor fragments were transplanted, its growth was estrogen-independent (Figure 2.7). 
This underscores the challenge of predicting origins or behavior of tumors based on a 
limited number of biomarkers.  
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Figure 2.11 Cellular origins of mammary tumors in BALB/c-Trp53+/- mice 
Mammary glands in BALB/c-Trp53+/- mice display normal ductal and alveolar 
structures composed of luminal (green) and basal cells (red). Progenitor cells (orange) 
with a potential to differentiate into both epithelial lineages also reside in the normal 
structure. Loss of the wild type allele of Trp53 in any of these cells would abolish the rate 
limiting step in tumorigenesis resulting in invasive mammary tumors. As the majority of 
mammary tumors contain tumor cells expressing luminal and basal markers, a clonal 
origin within bipotent cells is suggested as the most common pathway.  For tumors 
expressing only luminal or basal markers, there could be two possibilities. They may 
originate from bipotent progenitors and later partially-differentiate into tumors with 
single lineage cells or they could originate within the lineage-restricted cells. The overall 
similarity of the stem cell gene expression pattern of tumors suggested the former path.  
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As the majority of tumors expressed both luminal and basal keratins, it would 
appear that tumors initiate most often within stem cell/progenitor cells, and later 
differentiate into two (or more) distinct populations. It is possible that progenitor cells 
may be most susceptible to transformation, but decreased p53 function may also lead to 
expansion of the progenitor cell pool. The p53 protein plays a fundamental role in 
restricting the pool of stem cells in embryonic stem cells (67-69) as well as adult tissues 
including neuronal (73;145), hematopoietic systems (70;71) and mammary glands 
(74;75). In mammosphere culture of BALB/c Trp53+/+, Trp53+/- and Trp53-/- mice, 
haploinsufficiency is reflected on both the size of the mammospheres and the count of 
mammosphere initiating cells (unpublished data, L.Tao and D.J. Jerry). These results 
suggest an in vivo expansion of stem cell/progenitor pool in BALB/c Trp53+/- mice. 
Loss of p53 allows expansion of cancer stem cells either through asymmetric division or 
by promoting phenotypic plasticity and the acquisition of stem cell characteristics 
(119;146). Mammary tumors from BALB/c-Trp53+/- mice showed evidence of activated 
Wnt and Notch signaling. Aberrant signaling in these pathways could result in stem cell 
expansion and tumorigenesis in mammary glands (45;135;136). However, it remains 
possible that the tumors initiate within lineage-restricted cells and acquire the stem cell 
signature during progression.  
Basal-like tumors are among the five mammary tumor subtypes identified 
recently by microarray profiling of human invasive breast carcinomas. It frequently 
harbors p53 mutation and has poor clinical outcome (26;27). Microarray profiles on 
murine mammary tumor models reveals that tumors from Trp53 deficient models showed 
basal like features and shared significant association with the human basal-like tumor 
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subtype (37). We are the first to show parity is protective against mammary tumor from 
Trp53 heterozygous mice though human data is still unavailable (probably due to the 
early tumor incidence in Li-Fraumeni syndrome patients). Like Trp53-deficient 
mammary tumors, BRCA1-related hereditary breast cancers are also most commonly 
basal type (147;148). Up to 90% of BRCA1-associated tumors harbor TP53 alteration 
(149). Parity is protective against breast cancer in carriers of BRCA1 mutation (150). 
More interestingly, BRCA1 plays a critical role in the differentiation of ER-negative 
stem/progenitor cells to ER-positive luminal cells, and loss of BRCA1 function results in 
aberrant expansion of the stem cell pool in the human breast (151). Expanded bipotent 
progenitor cells were identified in breast tissues from BRCA1 mutation carriers and 
showed abnormal growth in vitro (140). Evidence is accumulating that an expanded 
stem/progenitor cell pool resides in histologically normal mammary glands in both p53 
deficient models and BRCA1 deficient models. While the hypothesis that parity alters 
mammary stem cell numbers to provide protection against breast cancer is still under 
investigation, the similarity of lineages markers in tumors from nulliparous and parous  
BALB/c Trp53+/- supports the progenitor origin. Better lineage markers and lineage 
tracing techniques are required to prove the stem/progenitor origin of malignant 
transformation. On the other hand, one should never exclude differentiated cells as tumor 
initiating cells. The multi-step tumorigenesis (accumulation of gene mutations) may 
accompany each step of replication/differentiation, while the last straw can just happen in 
any position of the cellular hierarchy.  
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CHAPTER 3 
 
 
USING MAGNETIC NANOPARTICLES FOR CANCER THERMOTHERAPY 
Introduction: 
Conventional cancer treatment involves a combination of surgery, chemotherapy 
and radiation therapy. Although often effective, significant damage is inflicted on healthy 
tissues and patients suffer from systemic side effects. Two types of targeting can be used 
to improve the current tumor therapy. First, tumors can be targeted spatially, with the 
toxic effect of the therapeutic agent localized to the tumor site only. The second type of 
targeting is to specifically direct treatment on tumor cells, sparing all normal cells in the 
vicinity. To achieve both of the goals, recent research has focused on regional heating of 
tumors using magnetic particles. 
Thermotherapy as Cancer Treatment 
Thermotherapy is a type of cancer treatment in which tumor tissues are damaged 
by exposing them to elevated temperatures. Under low pO2 and low pH conditions in 
most solid tumors, tumor cells are more vulnerable to modest temperature rise (up to 
46°C) while normal tissues are usually less sensitive (152). Elevation of tissue 
temperature above 40-41°C alters the function of many structural and enzymatic proteins 
within cells that can lead to apoptosis within hours or necrosis, if the temperature is 
higher than 46°C. Loss of membrane integrity, protein denaturation and inhibition of 
biochemical pathways have been implicated as the causes of cellular death (152;153). A 
few clinical trials have been conducted using hyperthermia as adjuvant therapy 
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(combined with traditional chemotherapy or radiation) for various types of cancers, 
including sarcoma, melanoma, and cancers of the head and neck, brain, lung, esophagus, 
breast, bladder, rectum, liver, appendix and cervix. Many of these studies have shown a 
significant reduction in tumor size compared to using traditional therapy alone (152;154).  
Common thermotherapy techniques include electromagnetic waves radiated by 
antennas (microwave or radiofrequency probes) (155;156), laser (157), focused 
ultrasound (158;159) and magnetically excited metal thermoseeds (160;161). While 
effective in producing heat, the macroscopic heating systems perform poorly on heat 
distribution, thus have limited efficacy with larger tumor volumes. Insufficient 
temperature rise in parts of the tumor results in treatment failure. However, extensive 
intratumoral temperature rise can induce damage to adjacent normal tissues. 
Two new approaches use nano-materials as a heating source to achieve better heat 
distribution: near-infrared laser induced thermotherapy and magentic field induced 
thermotherapy. In the former technique, metal nanoshells (162;163), nanorods(164), 
carbon nanotubes (165) provide selective heating to tissues upon exposure to intense 
near-infrared laser irradiation (NIR) from outside the body. The moderate penetration 
depth of NIR, however, limits the utility of this method in treating deep lesions in the 
body. Magnetic field induced thermotherapy uses alternating magnetic field (AMF, 
energy source) to heat nanoparticles (heat source) embedded within tissue (Figure 3.1). 
Animal tissue is essentially transparent to magnetic fields, and even quite strong fields 
are harmless to the human body (166). Furthermore, it can reach high cellular selectivity 
via tailored surface modification of the nanoparticle. In other words, thermotherapy using 
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AMF induced heating of nanoparticle can achieve localized, controlled heating in deep 
tumor tissue without damaging adjacent normal tissue. 
 
 
Figure 3.1 Inductive heating of magnetic nanoparticles 
Heat is produced by the imposed alignment of magnetic dipoles in an 
alternating magnetic field produced in a coil. (courtesy of Fischer N.F.) 
 
Heating of Magnetic Nanoparticles for Thermotherapy 
Up to now, all magnetic nanoparticles intended to be used in vivo are composed 
of magnetic iron oxides (167). The main reason for this is their low toxicity and the 
known pathways of metabolism. Magnetic nanoparticles in an alternating magnetic field 
produce heat by Néel and Brownian relaxation. In the process of Néel relaxation, the 
AMF induces the rotation of magnetic moments within the magnetic core. Heat is then 
dissipated when the particle moment relaxes back to its equilibrium orientation. In 
addition, a portion of heat is generated due to rotational Brownian motion, namely the 
motion of the whole particle due to the exerted torque of the AMF (168).  
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Magnetic nanoparticle-loaded liposomes (169), magnetic fluids (ferrofluids)(170) 
and magnetite-doped microspheres (171), have been utilized in hyperthermia and ablation 
therapies with varying success. Hilger et al demonstrated the ablation of tumors by 
intratumoral injection of ferrofluid (magnetic particles suspended in a carrier fluid) 
followed by alternating magnetic field, whereby temperatures of up to 71ºC were 
achieved in as little as four minutes using biocompatible field strengths (170). However, 
these particles required liposome or anionic surfactant to keep them stable and/or solube 
which limited their further application in biological systems. Actually, many iron oxide 
nanoparticles have a high tendency to agglomerate and thus to build larger structure even 
in the absence of a magnetic field.  It has a strong  influence on the magnetic properties 
of the particle and its biomedical applications.  
Water soluble superparamagnetic iron oxide nanoparticles (SPION), i.e. those that 
do not have a permanent dipole or domain wall which prevents undesired magnetic 
agglomeration even under the influence of an external magnetic field, are favored for 
biological applications. SPION coated and stabilized with hydrophilic polymers have 
been found to be quite thermodynamically stable under physiological conditions, not 
exerting obvious toxic effects (167). SPION with dextran or aminosilane coating have 
also been tested for thermotherapy (172). Aminosilane coated iron oxide nanoparticles 
(120 mg/ ml) were injected into transplanted prostate tumors in rats which then were 
exposed to 12.6 kA/m AMF for 60min. Intratumoral temperature reached 54.8ºC at 
maximal and 41-50% tumor growth inhibition was observed (173). DeNardo et al. 
reported the use of antibody conjugated dextran-coated iron oxide nanoparticle for 
targeted thermal cancer therapy (systemic injection) followed by application of a very 
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high magnetic field (700 Oe = 55.7 kA/m) (174). They observed a significant decrease in 
tumor growth. In these cases, heating capacity of these nanoparticles are largely reduced, 
due to polydispersity of the sizes of the nanoparticles, thus creating a need to use either 
high concentrations (with concomitant toxicity) or magnetic field strengths close to the 
lethal dose (173-175).  
These studies illustrate the potential of using iron oxide nanoparticles for 
magnetic-mediated thermal ablation of tumors, but chemical and biological 
improvements are needed in order to achieve its full potential. First, the heating capacity 
of magnetic nanoparticle largely relies on its size and degree of monodispersity (176). 
Maximal heating of iron oxide nanoparticles require core size around 14 and 20nm 
(Fe3O4 and Fe2O3, respectively), according to theoretical calculation. Optimizing 
magnetic nanoparticle core size and decreasing size polydispersity will greatly help 
realizing its full heating potential. The second is to tailor the particle surface to promote 
biocompatibility and specific interaction with target tumor cells. The ideal passivation 
should confer the particle its stability on shelf, biocompatibiltity in vivo and selective 
targeting on tumor cells to various extents. For example, folate receptor is highly 
expressed on a variety of cancers, especially ovarian cancer. A few normal tissues also 
express folate receptor, but at a much lower level than folate receptor positive tumor 
samples. Folate can be engineered onto nanoparticle surface as part of passivation as well 
as target molecule. The same principle applies to antibodies against tumor specific 
antigens, e.g. Her2/Neu in human breast cancer. 
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Materials and Methods 
Determination of the Particle Sizes 
TEM images were acquired on a JEOL 100CX operating at 100keV. Samples 
were drop cast from water solution, onto a copper coated grid, dried, and imaged. The 
particles’ size distribution, assigned as the standard deviation (SD), was measured using 
Image J software. 
Experimental Setup for Magnetic Thermotherapy 
An alternating magnetic field (AMF) heating system was purchased from MSI 
Automation, Inc. (Wichita, Kansas, USA). The experiment was performed inside a 
copper coil (diameter 10 cm), which produces an AMF at a fixed frequency of 400kHz 
and fixed amplitude of 6.3 kA/m. The experimental setup is depicted in Figure 3.2a. The 
temperature of the sample holder was maintained at 37±0.5ºC by using a thermal pad. 
The temperature for the experiments was measured by a DualLogR thermocouple 
thermometer (Eutech Instruments Pte Ltd, Singapore) with a TEF-30-T thermocouple (J-
KEM Scientific, Inc. St. Louis, MO, USA). The initial linear rise in temperature versus 
time dependence, dT/dt, was measured as illustrated in Figure 3.2b. The specific 
absorption rate (SAR) is defined as follows. 
SAR=(Cwater/c)dT/dt, where Cwater is the specific heat capacity of water and has the 
numeric value corresponding to 4185 J L/K, c is the sample concentration in g/L. 
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Figure 3.2 Experimental setup for magnetic thermotherapy 
(a) Schematics of the AMF device for alternating magnetic field thermotherapy. (b) SAR 
was measured using the initial slop of dT/dt. 
FT-Infrared Spectroscopy 
Infrared spectra were taken of KBr pellets formed from dry powder samples of 
BSA, iron oxide precursor and MNP-A using a MIDAC M1200-SP3 spectrophotometer. 
Dynamic Light Scattering (DLS) 
DLS samples were prepared using 5 mM sodium phosphate buffer (pH=7.4) and 
in milliQ water filtered with Acrodisc 0.2 µm filters (Pall Gelman Laboratory, Ann 
Arbor, MI). The NPs’ concentration was ~1 mg/mL. The measurement was performed 
on a Malvern Zetasizer Nano ZS instrument. Reported values of data are averages of nine 
measurements. 
Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis was carried out using a TA Instruments (New Castle, 
DE) TGA 2050 thermogravimetric analyzer. 4.4 mg of MNP-A was placed in a open 
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platinum pan and heated from room temperature to 800°C with a heating rate of 
10°C/min under acontinuous air purge of N2.  
Circular Dichroism (CD) 
Far-UV CD spectra of BSA, thermally denatured BSA and MNP-A were 
measured on a JASCO J-720 spectropolarimeter with quartz cuvettes of 1mm path length 
at 25ºC. The spectra were recorded from 190 to 250 nm as an average of three scans at a 
rate of 10nm/min. 
Stability Assays 
100 μL of nanoparticles (10 mg/mL stock in distilled water) was added to 1900μL 
of deionized water, or cell culture medium. UV-visible absorbance spectra (HP 8452 
spectrophotometer) were obtained for different time interval under room temperature.  
Cell Culture 
HeLa cells were grown in a RPMI1640 medium (Gibco BRL) supplemented with 
10% fetal bovine serum (Gibco BRL), MEM non-essential amino acids (Sigma), sodium 
pyruvate (1mM), sodium bicarbonate (0.15%, w/v) and antibiotic–antimycotic solution 
(100 µg/mL penicillin + 100µg/mL streptomycin + 0.25µg/mL amphotericin B) in an 
atmosphere of 5% CO2 at 37ºC. 
Thermal Effect of MNP-A on 2D Cell Culture 
8x104 HeLa cells/well were seeded in 4 well plates (200mm2/well) and incubated 
overnight. Then the culture medium was replaced by MNP-A containing medium for 2 h 
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followed by 45min magnetic field exposure. After AMF exposure, cells were 
immediately washed by PBS twice and subjected to cell viability assay. 
Cell Viability Assay 
Cell viability was measured by quantifying the reduction of a dye indicator alamar 
blue. Alamar blue is a dye that takes advantage of mitochondrial reductases to change 
from oxidized indigo blue state to reduced pink state. This dye has been successfully used 
in various cell cultures to measure cell viability (177;178). Briefly, cells in 4-well plates 
are loaded with 300µL culture medium containing 10% alamar blue (Biosource 
International) and incubated in 37ºC, 5% CO2 for 2 h. 100µL medium from each well 
was then transferred to a 96-well plate and subjected to measurement. The reduction of 
alamar blue was measured and calculated by a SpectroMax M5 micro-plate reader 
(Molecular Devices, Inc.) at 570 nm and 600 nm wavelengths. 
Cell Staining 
HeLa cells were incubated in MNP-A (4 mg/mL) containing medium for 2 h under 
cell culture conditions. After washing with PBS, cells were fixed with methanol at -20ºC, 
washed with PBS, incubated for 15 min in a solution of 2% potassium ferrocyanide 
(Sigma P9387) in 2% HCl, washed, and counter stained with eosin. 
Quantification of Cell-bound MNP 
Procedure for quantifying total cell-bound iron was based on published literature 
using Prussian blue reaction (179). Briefly, harvested MNP treated cells from 6-well 
plates were dissolved in 6N HCl (125µL/well) overnight. Then 125µL of 5% 
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K4[Fe(CN)6] was added into each sample. After 10min incubation, the absorbance was 
read at 690nm in SpectroMax M5 micro-plate reader. A standard curve of an aqueous 
FeCl3 solution was treated in the same conditions to quantify the amount of cell-bound 
iron. Detailed protocol see Appendix. 
Colony Formation Assay   
After treatments, cell pellets were resuspended in 10mL culture medium and total 
live cells were counted using trypan blue staining. Cells were seeded into 60mm cell 
culture dishes at 1500 cells/dish. and culture for 7-10 days with no disturbance. Cell 
dishes were then fixed with 10% neutral-buffered formalin at room temperature for 
10mins, washed with distilled water. Each dish was stained with 1% crystal violet for 
5min followed by tap water rinse. Visible colonies were counted by G-box system. 
Results *
Heating capacity and biocompatibility of iron oxide magnetic nanoparticles 
 
The heating capacity of NPs was assessed by the surface absorption rate (SAR). 
When conditions of alternative magnetic field are fixed, SAR is mostly dependent on 
particle size and distribution. Numerous attempts were made in the chemistry lab (Dr. 
Rotello) during the course of the study to produce desired MNP.   
Five iron oxide nanoparticles passed initial tests (SAR and water solubility) and 
were brought to in vitro biocompatibility test (Table 3.1). The albumin passivated 
                                               
* Most of the data in this chapter is published in Journal of Materials Chemistry, 2008 
(180), except "Heating effects of cell bound MNP-A" 
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magnetic nanoparticle (MNP-A) surpassed other nanoparticles showing efficient heating 
with very low inherent cytotoxicity.  
 
Table 3.1 Features of magnetic nanoparticles in current study 
Particle 
passivation 
Core size 
(nm) 
Surface 
charge 
SAR* 
(W/g Fe) 
Solubility 
in PBS 
Solubility in cell 
culture medium 
w/ serum 
Toxicity§ 
-NH2 22 + ~10 yes yes high 
-citrate 12 - 20ǂ yes visible aggregation low 
-folate 12 - 20 yes partial aggregation in 24hrs not tested 
-N(CH3)3 12 + 36± no Yes (trace of precipitation) low 
-BSA# 12 - 36 yes yes very low 
* SAR: specific absorption rate, heating capacity were measured under AMF (400kHz, 
6.3kA/m) 
# BSA: bovine serum albumin 
§ Toxicity test: Viability of HeLa cells tested after treating with culture medium 
containing MNP for 6hrs (Figure 3.3). Alamar Blue cell viability kit were used for 
viability test. 
±  Magnetic separation were performed to collect larger size nanoparticles. 
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Figure 3.3 Toxicity test of MNPs.  
HeLa cells were treated with various MNPs at different concentrations for 6hrs. After the 
treatment, cells were subjected to alamar blue cell viability test. Each testing point 
represents 4-6 replicates. 
 
 
Features of albumin passivated magnetic nanoparticle (MNP-A) 
The synthesis adopted a modified Massart's co-precipitation method to provide 
"naked" nanoparticles suitable for facile functionaliztion. Bovine serum albumin (BSA) 
passivation of the iron oxide core was performed via ultrasonication of the particle in the 
presence of excess BSA. BSA coated iron oxide (MNP-A) nanoparticles were isolated 
from excess BSA solution via ultracentrifugation (Figure 3.4a). The TEM micrograph of 
MNP-A revealed the NP core was 12.1±1.6 nm in diameter (Figure 3.4b). 
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Figure 3.4 Synthesis, structure and size of MNP-A 
(a) BSA was incorporated as MNP coating using ultrasonication; (b) Transmission 
electron microscopy (TEM, left) and histogram (right) of MNP-A core size (d=12.1±1.6 
nm)  
 
 
BSA is an anionic protein with a pI of 4.8, so it is likely that adsorption of the 
BSA onto the NP occurs through anionic functionality of the BSA. The presence of BSA 
on the NP surface was confirmed by Fourier transform infrared (FT-IR) spectroscopy, as 
the characteristic bands of the BSA protein at 1660 cm-1 and 1530 cm-1 are both present 
in the FT-IR spectra of MNP-A (Figure 3.5a). In addition, thermogravimetric analysis 
(TGA) was conducted to quantify the amount of adsorbed BSA (Figure 3.5b). The 22.5% 
weight loss observed from TGA of MNP-A corresponds to ~13 BSA molecules per iron 
oxide core. The adsorption of BSA to the NP core results in partial denaturation of the 
protein (Figure 3.5c). Considering the size of BSA (8.4nm), the thickness of the protein 
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shell on the nanoparticle would be ~8 nm, therefore the overall diameter of MNP-A 
would be ~28nm. In aqueous solution, the average hydrodynamic size of MNP-A is 50±5 
nm, measured by dynamic light scattering (DLS) (Figure 3.5d). The increase in 
hydrodynamic diameter of MNP-A suggests that there is minor particle aggregation. 
 
 
Figure 3.5 Characterization of MNP-A 
(a) FT-IR spectrum of BSA (blue), iron oxide core (black) and MNP-A (green). b) MNP-
A showed 22.5% weight loss on TGA test (c) Circular dichroism spectra of BSA, MNP-
A and thermally denatured BSA. d) DLS analysis of MNP-A in H2O and PBS. 
 
MNP-A showed excellent long-term solution stability, remaining stable in 
deionized water for more than 2 months. No aggregation was observed under a variety of 
conditions, including deionzed water, and cell culture medium (Figure 3.6).  
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Figure 3.6 MNP-A showed stability in H2O and cell culture medium.  
Both MNP-A and MNP-citrate were prepared at 0.5mg/ml in water and cell culture 
medium. UV-visible absorbance spectra were obtained at different time points up to 
50hrs under room temperature. MNP-A were stable in both solvent throughout the test, 
while MNP-citrate precipitated in cell culture medium.  
 
 
Alternating magnetic field induced MNP-A heating on 2D cell culture 
Thermal effects of MNP-A under AMF was first tested in cultured cancer cells. 
HeLa cells were incubated with MNP-A for 2 h followed by 45 min of magnetic field 
exposure (400 KHz, 6.3 kA/m). As a control, cells were also treated with MNP-A alone 
or AMF alone, or medium only. Immediately after treatment, cytotoxicity was measured 
among the treatments. The cells incubated with NP concentrations of more than 4 mg/mL 
subjected to the magnetic field showed total cell death after treatment, whereas cells that 
were treated with particles but without exposure to the magnetic field were unaffected, 
even at much higher NP concentrations (Figure 3.7). As expected, control cells that were 
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exposed to the magnetic field in the absence of NPs showed no decrease in the cell 
viability. In this experimental setup, cancers cells were abolished by the temperature rise 
due to the MNP-A heating under AMF. It demonstrates that MNP-A provides a selective 
tool for AMF-induced ablation, as well as useful dosing information for future animal 
study. 
 
 
 
Figure 3.7 Thermal effect of MNP-A on cell culture 
HeLa cells were incubated with MNP-A for 2 h followed by 45 min magnetic field 
exposure. After AMF exposure (400kHz, 6.3kA/m), cells were immediately washed by 
PBS twice and subjected to a cell viability (10% alamar blue reduction) assay, with cell 
death being confirmed by trypan blue staining (data not shown). Inset: Heating effects at 
4mg/mL MNP-A. 
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Heating effects generated by cell-bound MNP-A under AMF 
With prominent bulk heating effects established, MNP-A was further examined 
on its interaction with individual cells. Perls Prussian blue staining of MNP-A-treated 
HeLa cells revealed a high density of nanoparticles on the cell surface (Figure 3.8a). 
MNP-A was not only attached to the cell surface, they were also abundant in cytosol and 
cell nuclei (Figure 3.8b). We regard these MNPs as cell-bound MNPs which include 
particles that tightly attached to cell surface as well as internalized nanoparticles. It is 
likely that MNP-A is internalized into cells by endocytosis and phagocytosis (181). The 
amount of cell-bound MNP-A showed a tendency of MNP concentration dependence and 
incubation time dependence during the 48hrs study period. After the cells were treated 
with 2mg/ml MNP-A for 48hrs, cell bound MNP-A can reach as high as 12pg Fe/cell 
(Figure 3.8c).  
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Figure 3.8 Interaction of MNP-A with cultured HeLa cells 
(a) HeLa cells were incubated in medium with 4mg/mL MNP-A or without for 2hrs, 
followed by Perls Prussian blue staining. MNP-A appeared as blue precipitates on the cell 
cytoplasm (left) while no iron was detected in the control (right). (b) Confocal 
microscopic image of HeLa cells incubated with MNP-A-FITC (0.5mg/mL for 24hrs), 
cell nuclei were stained with DAPI. (c) HeLa cells were treated with MNP-A (0.5, 1.0, 
2.0mg/mL) for 6, 24 or 48hrs. Cell bound MNP-A were quantified by the amount of Fe 
using Prussian blue reaction. 
 
 
Will the amount of cell-bound MNP-A generate enough heating effect in vivo 
under biocompatible AMF? We used cell pellets (by centrifuging cultured cells) as in 
vitro model to mimic heating in solid tumors. After treating with 2mg/ml MNP-A for 
48hrs, HeLa cells were washed with PBS, digested with trypsin and spun down into cell 
pellets.  Cell pellets from MNP-A treated and MNP-A-untreated samples were then 
subject to AMF (400kHz, 6.3kA/m). The amount of MNP-A bound to HeLa cells 
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successfully produced rapid heating, sample temperature rose from 37ºC to 42ºC in 8 
mins (Figure 3.9a). Instead of high temperature rise causing direct cytotoxic effects 
leading to necrosis, mild temperature rise usually impairs functions of cellular proteins, 
stops cell proliferation and ultimately causes apoptosis. To include this chronic 
cytotoxicity effect, we used colony formation assay to test cell-bound MNP-A heating 
effects on cell pellets.  After the 60 mins AMF treatment, HeLa cells in pellets were well 
resuspended and further diluted for seeding in 6cm culture dish. After 7-10 days cell 
culture incubation, cell colonies were counted on each plate and compared among four 
treatment groups: MNP+AMF; MNP + No AMF; No MNP+ AMF; and No MNP+ No 
AMF (Figure 3.9b). The cells "bounded" with MNP-A and subjected to the magnetic 
field showed 70% fewer colonies compared to non-treatments group, whereas cells that 
were treated with particles but without exposing to the magnetic field were unaffected. 
However, the AMF only groups also showed 18% fewer colonies, suggesting weaker 
AMF strength is needed. 
  
 
 
Figure 3.9 Heating effects generated by cell-bound MNP-A under AMF 
HeLa cells were incubated with 2mg/ml MNP-A (or without) for 48hrs, followed by 
extensive PBS washes. Cells were then centrifuged into cell pellets before 1hr exposure 
to AMF(400kHz, 6.3kA/m). (a) Temperature record of the cell pellets. Arrows indicate 
the start and end of AMF. (b) After the treatments, cell pellets were re-suspended in 
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culture medium and subjected to colony forming assay. Cell colonies were counted 7-10 
days after seeding.  
 
Discussion 
Current cancer thermotherapy is a physical therapy with fewer limitations than 
chemotherapy or radiation therapy. It is typically used in combination with both of these 
therapies. It potentially allows a greater number of repeated treatments without 
accumulation of systemic toxic side effects. Although successful in numerous clinical 
trials (152;154), thermotherapy is not yet established in clinical routines. This 
discrepancy is probably due to current technical limitations in achieving effective 
temperature distribution in the depth of the human body (154). 
The heating of tissues using magnetic nanoparticles as a new technique for 
thermotherapy has the potential to overcome the shortcomings of current methods. The 
core task of this new technique for thermotherapy resides on developing biocompatible 
magnetic nanoparticles with high heating capacity.  
Compared to organic polymer as nanoparticle coating, we have developed a non-
toxic iron oxide NP that employs protein (BSA) as a biocompatible passivation agent. 
Among the handful of particles we studied, the heating capacity of MNP-A surpasses 
others without any magnetic separation and purification steps. The MNP coated by 
dextran or aminosilane are most commonly used in animal studies of magneticity induced 
thermotherapy. The SAR of dextran and aminosilane MNPs were reported at 120 and 146 
W/g Fe respectively, under AMF 13.2kA/m, 520kHz (172;182;183). However, unless we 
can obtain these MNP samples, it is almost impossible to compare SAR with other 
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published data, as they were all reported under different AMF strength and amplitude.  A 
brief feature comparison is provided in Table 3.2 
Table 3.2 Comparison of MNP-A with dextran and aminosilane coated MNP 
MNP features MNP-A #P6 #BU48 
MNP coating Albumin Dextran Aminosilane 
Average core size (nm) 12 3.3 13.1 
Core size distribution monodispersed polydispersed N/A 
Average hydrodynamic 
diameter 45-55 50-70 17 
Surface charge Negative Negative Highly positive 
Cell toxicity Very low Very low Very low 
AMF condition 6.3kA/m, 420kHz 13.2kA/m, 520kHz 
SAR W/g 36 120 146 
N/A: not available 
 
MNP-A is stable in a variety of media, and shows very low inherent toxicity on 
cells. It provides very rapid and efficient heating under AMF conditions that the amount 
of cell-bound particles are sufficient to generate detectable heating and killing effects. 
Furthermore, the BSA coating provides a platform for future incorporating targeting 
molecules to realize targeted tumor thermal therapy for animal studies. 
Various tumor targeting molecules have been proposed and even tested in animal 
models. These folate- (184), homing peptide- (185), or tumor specific antibody- 
(174;186) conjugated MNPs were intravenously injected into rodents bearing palpable 
tumors. The conjugation of these molecules largely enhanced the binding of MNP to 
tumor sites, which consequently delivered therapeutic heating effects under AMF. 
However, the equivalent MNP accumulation in liver, spleen and kidney cannot be 
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overlooked. Following intravenous injection, MNP are rapidly taken up by 
reticuloendothelial system (RES), mainly the kupffer cells in the liver and the spleen 
macrophages (187). These two organs accumulate more MNP than tumor site even in the 
presence of target molecules. Three strategies may be considered to lower collateral 
damage to liver, spleen and other organs during AMF induced thermotherapy. First, 
optimize MNP surface to reduce RES uptake. For example, smaller hydrodynamic size 
(<100nm) or hydrophilic surface evades RES uptake. Second, selectively treating tumors 
which can be spatially target by AMF. Tumors that are further away from abdomen can 
be good candidates, e.g. osteosarcomas in the limb, or brain tumors. The third strategy 
uses the inherent magnetic property of MNP. When MNP is injected in a selected artery 
supplying the region of interest (e.g. tumor site), under the influence of an external 
magnetic field, MNP will be held and concentrated in the targeted area (188;189). The 
localized accumulation of MNP-A and high permeability tumor vasculature will enable a 
much even distribution of MNP, thus better heating effects, and less systemic toxicity.  
Overall, MNP-A potentially provides a versatile platform to achieve better 
treatment of solid tumor, addressing the need for minimally invasive treatment that is 
effective and has low systemic side effects. 
 67 
APPENDICES 
 
 
1.  CYTOKERATIN EXPRESSION IN TUMORSPHERE CELLS FROM 
MAMMARY TUMORS IN BALB/c Trp53+/- MICE 
Introduction 
A variety of human malignancies, including breast cancer, are thought to be 
organized in a hierarchy, whereby a relatively minor population of tumor initiating cells 
(TIC) is responsible for tumor growth and the vast majority of remaining cells are 
nontumorigenic (51-56). As the majority of mammary tumors in the BALB/c Trp53+/- 
mice express both luminal and basal keratins, we proposed that the tumors initiated most 
often within stem cell/progenitor cells, and later differentiated into two (or more distinct) 
populations. Further gene expression array revealed a similar stem cell gene expression 
pattern between tumors with mixed cytokeratin expression and tumors expressing only 
luminal markers (Figure 2.9). It is likely that the tumors expressing only luminal or basal 
marker originate from similar progenitor cells. 
  Recently Zhang et al. identified tumor initiation cells in spontaneous mammary 
tumors from mice transplanted with synergetic Trp53-/- epithelium cells (119). Analysis 
of biomarkers suggested the tumor initiating cells population may arises from a bipotent 
mammary progenitor, and later differentiate into one or more lineage specific 
populations. Our data concurs with their finding. 
To further explore the possible cellular hierarchy and path of differentiation 
within each type of tumor, we used in vitro tumorsphere method (190;191) to enrich the 
"tumor stem cells". Under low attachment culture condition, a small portion of tumor 
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cells survive and form floating cell balls (tumorspheres) consisting of 10-100 cells.  
Undifferentiated tumor stem cells are enriched in tumorspheres, and can be induced to 
differentiate when put into attachment culture. 
Experiments and Results 
Tumor fragments from V06 and V14 were transplanted into mouse (wild type) 
mammary fat pad cleared of endogenous epithelium. Mice were sacrificed when tumor 
growths reached 1cm in diameter. Cells were isolated from tumor outgrowths into single 
cell suspension and then cultured in low attachment cell culture flasks. Individual tumor 
cells grow into sphere like balls (mammary tumorsphere) and were passaged every 3-5 
days. During each passage, a portion of the cells were plated into regular culture flasks 
(to induce differentiation). Mammary tumorspheres and induced cell cultures were 
subjected to immunofluorescent staining on K5 and K8/18. 
  The tumor growth from transplanted fragments (designated as T) expressed 
similar cytokeratin pattern as original tumors (data now shown). V06 tumor (and its 
outgrowth from transplanted fragments--V06T) expressed both K5 and K8/18. Most cells 
in V06T tumorspheres were negative for both K8/18 and K5. A small portion of the cells 
close to the surface of the spheres expressed K8/18 or K5 (Figure A.1, A-D). On the 
other hand, a majority of cells in attachment culture (induced differentiated cells) 
expressed K8/18, K5 or both (Figure A.1, E-G).  
V14 tumor (and its outgrowth from transplanted fragments--V14T) expressed 
only K8/18. Cells in V14 tumorspheres were mostly negative for both K8/18 and K5 too. 
Surprisingly, not only K8/18 positive but also K5 positive cells were detected in V14T 
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tumorsphere (Figure A.1, K-N). In attachment culture, cells with positive cytokeratin 
stain largely increased. K8/18 positive, K5 positive, double positive and double negative 
cells were seen (Figure A.1, H-J).  
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Figure A.1 Cytokeratin expression in mammary tumorspheres.  
V06 and V14 fragments were transplanted into mammary fat pads that had been cleared 
of endogenous epithelium in BALB/c-Trp53+/+ hosts. Isolated tumor cells from the 
outgrowth (V06T and V14T) were cultured in low attachment plates and formed 
mammary tumorsphere. Tumorspheres from V06T contained cells expressing K8/18, K5, 
both or neither (A-D, the structure of the sphere was shown in D). In regular attachment 
culture, cells from the V06T spheres attached to the bottom surface and expressed K8/18, 
K5, neither or both (E-G, orange arrow indicates a double positive cell). In regular 
attachment culture, cells from the V14T spheres expressed K8/18, K5, both (orange 
arrow) or neither (H-J). Though tumorspheres from V14T contained mostly cells negative 
for both K8/18 and K5, positive cells were occasionally seen near the surface of the 
spheres. In one tumorsphere, K and L shows a transverse plane near the top of the sphere, 
whereas M and N is a transverse plane in the middle of the sphere. K8/18 positive (K) 
and K5 positive (M, red arrowhead) cells are seen in the sphere.  
 
Discussion 
Based on epithelial lineage specific cytokeratin staining, we proposed that the 
majority of BALB/c Trp53+/- mammary tumor originate from bipotent mammary gland 
progenitors, and others from lineage-committed progenitors (Figure 2.11). As we have no 
means to trace tumorigenesis on single cell level, we cannot exclude the possibility that 
tumor initiating cells can be newly created from differentiated cells by certain mutations 
that reactivate genes regulating stem cell behavior (self-renewal and multipotential 
differentiation) (192-194).  Cytokeratin expression pattern of mammary tumors in 
BALB/c Trp53+/- mice could be the outcome of random mutation and growth 
competition/selection within each tumor. The in vitro mammary tumorsphere assay 
supports this possibility, as the K8/18 positive, the K5 positive, the double positive and 
the double negative cells were all detected in both V14T and V06T.  
Actually, creating tumor initiating cells by mutating normal stem cells or by 
reactivating stem cell properties in differentiated cells may not be mutually exclusive 
possibilities, and both could help explain the enormous biological diversity observed 
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within and between mammary tumors. Some cancers may even contain multiple stem 
cells, contributing to intratumor diversity. Depending on the accumulated gene mutations,  
transformed somatic cells may develop into heterogeneous tumors, too.  
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2.  TESTING MAESTRO IN VIVO FLUORESCENCE IMAGE SYSTEM  
Introduction 
  My original experimental plan involves using in vivo image system to track 
metastasis in mice transplanted with BALB/c Trp53+/- mammary tumors. I tested the 
Maestro system in vivo image system resided in Pioneer Valley Life Institute using a 
established metastasis cell line, but was unimpressed about the results. Here I quote from 
Maestro official website to introduce the key features of the system: 
 
Maestro systems enable multiplexed in vivo fluorescence imaging of small 
animals with unprecedented sensitivity. Maestro offers users the capability of removing 
autofluorescence emitted from images of skin and other tissues to reveal otherwise hard-
to-detect labeled targets. The dramatic improvement in signal-to-noise can increase 
sensitivity up to several hundred-fold, enabling much smaller or fainter signals from 
biological targets to be detected earlier and accurately measured. The increased 
sensitivity over standard imaging techniques provided by Maestro’s high-quality spectral 
imaging technology enable experiments and models which simply cannot be done with 
any other system. 
Experiment and Results 
4T1 cell line is a established murine metastatic cell line. Palpable tumors can be 
detected within 2 weeks of subcutaneous injection (s.c.). Metastasis can be detected 
within a month after primary tumor is removed. So 4T1 cell line was perfect for 
preliminary test on Maestro system.  
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We were suggested by manufacturer to avoid using green fluorescent protein as it 
has strong interference with autofluorescence from mouse hair and skin. mOrange vector 
was obtained from Tsien R.Y. Lab. The fluorescence gene was reconstructed into a 
retrovirus vector generating mOrange-pQCXIP (Pcmv-mOrange-IRES-Purr). 4T1 cells 
were infected with the vector and placed in culture medium containing Puromycin for 
selection. Three weeks later, 4T1-mOrange cell line was established although I found 
there was only 60% of the cells are fluorescent (Figure A.2). Highly fluorescent cells 
were sorted out and plated in confluent density to avoid rapid replication which may 
result in losing fluorescence gene. These cells were harvested on the 2nd day after sorting 
to. injected s.c into wild type BALB/c mice (5x104/mouse).  
 
 
 
Figure A.2 4T1-mOrange  
Highly florescent 4T1-mOrange cells were sorted for injection 
 
 
Palpable tumors were detected two weeks after injection. On the day of imaging, 
mice were anesthetized using Tribromoethanol (Avertin®). They were then shaved and 
treated with Veet® hair removal foam for 10min to expose skin for imaging area. After 
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imaging, primary tumor were quickly removed and skin were sutured with absorbable 
suture. Mice were kept on heating pad whenever possible to keep body temperature.  
Mice were monitored 2 times/week for signs of metastasis, such as visible or 
palpable lump, body weight lost, or any sick signs. When metastasis signs were observed, 
usually 4 weeks after primary tumor were removed, mice were taken to imaging 
following the same procedure during primary tumor imaging. After imaging, mice were 
sacrificed and autopsies were conducted to compare imaging results with autopsy results. 
Maestro system can detect primary tumor very well as they are always right under 
the skin  
Figure A.3.  
  
 
Figure A.3 Maestro system detecting primary tumor 
Maestro image showed exact size and shape of primary tumor. There is a small skin 
rupture (arrowheads) on the tumor and the image system seems very sensitive to 
unevenness on the skin and gave out strong signal. The darker parts (arrows) of the image 
may be the vessels and necrosis of the tumor which didn't have fluorescence.  
 
However, the performance of the system on metastasis sites were below 
expectation. For example, a mouse without visible metastasis (Figure A.4) were subjected 
to imaging. One fluorescent spot (Figure A.4A, yellow arrow) were detected in the live 
animal and its correspondent one was found in the autopsy (Figure A.4B, yellow arrow). 
However, the system missed one fluorescent site (Figure A.4C, green arrowhead). The 
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fluorescence was visible under Maestro system after the skin was removed, but the 
system missed during the in vivo imaging. The missed lesion was just slightly deeper 
from skin compared to the detected one.  The autopsy showed the real physical lesion 
was bigger (Figure A.4D green arrowhead). A possible explanation is that part of the 
metastasis foci was not fluorescent, which was quite often seen during the whole 
experiment. Even though cells were sorted before injection, more than half of the visible 
metastatic site did not show fluorescent even in autopsy stage. Metastasis process may 
select tumor cells against extra fluorescent gene burden. Nevertheless, the presented data 
was one of the four mice I tested and it is sufficient in telling the story. Overall, the 
Maestro system prove to be unable to detect fluorescent metastatic foci that are not 
directly under the skin.  
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Figure A.4 Maestro system detecting metastatic tumor sites 
One fluorescent spot was detected in vivo (A, yellow arrow) and it matched the autopsy 
result (B, yellow arrow). The same spot can also been seen in the zoom-in view of C and 
D. However, the system missed the other fluorescent spot which were revealed during 
autopsy (C, D green arrowhead). There are non-fluorescent foci found (D, purple thick 
arrow). 
A B 
C D 
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3.  PROTOCOLS 
Isolate tumor cells from mammary tumor tissue 
Materials 
Dissecting tools 
Cotton swabs 
Sterile scalpels/ Razor blades 
MECL medium (2%ABS) 
Collagenase III (Worthington ) 
Hyaluronidase  Sigma #H3506 
Pen/Strep Gibco 100× 
Gentamycin Gibco  
24 well plate or equal surface area 4 well plate 
Day 0 
Autoclave dissection tools 
Day 1 
1. Make collagenase solution (Digestion medium) 
 
  DMEM:F12 100ml 
  5% FBS 
  100u/ml pen/strep (1ml), Stock 10mg/ml 
  100µg/ml gentamicine (0.2ml), Stock 50mg/ml 
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  2mg/ml collagenase (200mg)  
 
2. Take tumor sample from mice 
3. Use sterile technique, mince tumor tissue into very small pieces (<0.5mm) with 
two razor blades. Mincing should not take more than 5min. Place minced tissue in 
digestion medium (0.5g tissue/10ml medium in 15ml conical tube, about rice size) 
and shake at 37 ºC for approximately 3 hrs. The shaker should be set at 110 to 125 
rpm. (Give it a good, hard shake every hour) 
4. Centrifuge to collect cells after collagenase digestion. PBS wash once. The result 
pellet is resuspended in MECL media with 2%ABS, pen/strep and gentamycin. 
Seed cells in 3-4 wells in 6 well plates (per 0.5g tissue). Change to fresh medium 
after 6hrs. 
5. In the following weeks, passage cells into the same size culture surface until 
obvious cell growth are observed.  
6. Freeze vials along the way. 
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Immunofluorescence stain (K5, K8/18) 
Materials and Solutions 
Antibodies 
• Anti-cytokeratin 5 (K5, 1:8000, PRB-160P, Covance, Berkeley, CA) 
• Anti-cytokeratin 8/18 (Ker8/18, 1:450, GP11, Progen Biotecknik, Heiderlberg, 
Germany) 
 
Coverslip: 22x22mm, 1 ½,  (check the lens to decide optimum thickness) 
 
Sodium citrate 100mM: 
29.14g (sodium citrate.2H2O) + 1L H2O 
 
Blocking buffer:  
5%BSA/0.5%Tween-20 in 1X PBS  
0.5g BSA + 0.05ml Tween-20 in 10ml PBS (fresh preparation, no more than 1 
week old, keep in 4ºC) 
 
Wash solution:  
0.1%Tween20 in PBS 
0.1ml Tween 20 in 100ml PBS 
 
Equilibrate solution 
Mounting medium w/o DABCO 
 
Homemade mounting medium 
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DABCO/Tris/Glicerol (DTG) 
2.5% Dabco (Sigma D2522) 
50mM Tris-HCl pH8.0 
90% Glycerol 
for 50ml use 1.25g DABCO, 45ml glycerol, 2.5ml 1M Tris pH8.0 and 2.5ml H2O. 
Mix components, dissolve DABCO by warming to 70ºC, mix, aliquot and store at -
20ºC. Stable at 4ºC for 1 month (watch for contamination).  
Procedure: 
1. Deparaffinize and rehydrate sections as follows: 
3 x 3´ Xylene 
3 x 3´ 100% ethanol 
2 x 2´ 95% ethanol 
2 x 2´ 70% ethanol 
1 x 5´ 1x PBS 
 
2. Microwave antigen retrieval: 
• Place slides in a glass slide holder and fill in the rest of the rack with blank 
slides (10 total). 
• Place the rack in 600 ml of 10 mM Sodium Citrate (pH 6; 100 mM stock) in 
a glass 2L beaker. 
• Microwave for 20 minutes total, replacing evaporated water after 10 min. 
• Cool the slides 20 min in the beaker. 
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• Wash 3 x 5´ in ddH2O, 1 x 5´ in 1x PBS 
 
3. Shake/wipe off excess PBS and circle all sections with a PAP pen. Do not let the 
sections dry out. 
4. Add 50 μl of blocking buffer to each. Incubate 1-4 hours (1hr is sufficient) at 
room temperature in a humidified chamber. 
5. Dilute primary antibody in blocking buffer. Anti-K5 (1:8000), anti-K8/18 (1:400). 
Add 50 μl of diluted antibody per section and incubate overnight (I didn’t try 
shorter time) at room temperature in a humid chamber (need to be very humid, 
otherwise slides will dry out, also make a second PAP pen circle if the first one 
looks weak).  
6. Wash 10 times with washing buffer with the aid of a dropper. 
7. Apply secondary antibodies (1:200) + DAPI (1ug/ml) in PBS for 2hrs in a humid 
chamber. PROTECT FROM LIGHT!  
8. Wash as in step 6. 
9. Equilibrate 2X5min at RT with equilibration solution. This step helps removing 
salts and switching to mounting compatible buffer. 
10. Remove as much remaining fluid as possible. 
11. Finish by adding a drop of mounting solution and covering with a coverslip. 
Squeeze extra mounting solution out with help of bibulous/lens paper otherwise 
result in insufficient mounting. 
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12. Seal off with non-fluorescent nail polish. Let the polish dry for 10min. Keep 
slides at 4ºC at least ON. Take image the day after. Slides can be kept in  -20ºC 
for long term. 
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Quantification of cell-bound iron using Perls Prussian blue reaction  
Materials 
K4[Fe(CN)6] (Sigma P9387) 
FeCl3 
Procedures 
Prepare the K4Fe(CN)6, (5% in 2%HCL) 
100mg K4Fe(CN)6 + 2ml H2O + 40µL saturated HCl, in 50ml Felcon tube. Shake 
to solve. Use fresh. 
 
Standard curve 
Prepare 10mg/L Fe3+ stock solution using FeCl3. Dilute standards as follows. 
No Stock+H2O Vol(µl) Fe(µl/L) 
1 1500µl +       0µl 1500 10000 
2 1200µl +   300µl 1500 8000 
3   900µl +   600µl 1500 6000 
4   600µl +   900µl 1500 4000 
5   450µl + 1050µl 1500 3000 
6   300µl + 1200µl 1500 2000 
7   150µl + 1350µl 1500 1000 
8       0µl + 1500µl 1500 0 
 
Day 0: 
Seed HeLa cells in 6 well plates in culture medium, so that each well will reach 95-
100% confluency on day 1. 
Day 1: 
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1. Carefully remove the culture medium and load medium containing MNP-A at 
various concentrations e.g. 0, 0.5, 1, and 2mg/ml.  
2. Return the plates to cell culture incubator for 0, 6, 24 or 48hrs. 
3. After the treatment is done, wash each well with PBS for 2 times. 
4. Digest cells using 300µl 0.05% trypsin for 2 mins. 
5. Add 2-3ml culture medium to wash down cells and transfer each well into a 15ml 
conical tube. 
6. Take 10µl cell suspension from each tube for cell counting. Calculate how many 
cells each well has. 
7. Pellet cells down at 1200rpm for 5min. 
8. Resuspend cells in 1ml PBS and transfer to 1.5 Eppendorf tubes. 
9. Pellet the cells down at 2000rpm for 5min, and aspire the supernatant. 
10. Add H2O to each tube to reach 100µl total volume. 100µl from each standards 
will be treated in the same condition from now on. 
11. Add 125µl 6N HCl, mix well (vortex if needed) 
12. Incubate O.N at R.T. 
13. Centrifuge at 13000rpm for 5min.  
14. Transfer supernatant to a new 1.5 eppendorf tube for total iron test. 
15. Dilution was needed in all test samples in order to fit in standard curve range. 
16. Transfer 225µl diluted supernatant to a well in 96 well plate for total iron test. 
17. Add 125µl of 5% K4[Fe(CN)6] into each well and mix. 
18. Incubate at RT for 10min. 
19. Read the absorbance at 690nm. 
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4.  MSI AUTOMATION SYSTEM 
Originally written by Nick Fisher, modified by Haoheng Yan. 
 
The machine need water to cool down when it is running. 
No metal in the coil, it will heat up really high and quick. 
 
Turn it on: 
1. Turn on the cold water, the gauge will be 30-40 
2. Insert the key and turn it on. “→” →  “↑” 
3. Turn the big red knob to “on”  . Should hear the instrument running. 
4. Place the sample in the middle of the coil. Don’t put any metal around the coil. 
The space in the coil can fit a 4 well plate well which will get equal heating in the 
wells. 
5. Hit the “NO” (it should have been ON, but the button was installed upside-down) 
6. The instrument will start self-checking automatically with the yellow button 
indicating the steps. If everything is fine, no lights should be on after the 
checking.  
7. Select the  Timer│Hand switch for different running mode. Timer will let the 
magnetic field run under control of the timer, while the hand pedal stands for the 
pedal control. 
8. To change the time on the Timer, first unlock the timer, set the time using the 4 
buttons and the green number indicates the time you set. Then hit the reset to 
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confirm the running time to be one you set. The red number indicates the real time 
which the machine is going to refer. 
9. Use pedal to start the magnetic field. If it is under timer mode, the pedal is a 
starter, the real running time is according to what has been set on the timer. If it is 
under hand mode, the magnetic field is only on when the pedal is hit and hold.  
10. Use the tuner to adjust the AMP. Don’t exceed the max AMP. The FREQ is set to 
be around 400 kiloHz. Only the company could change it. 
Shut it down: 
1. Switch to Hand. 
2. Make sure the field is off. No bars on AMP and FREQ, “FREQ check” and 
“heater on” light is off 
3. Hit the “off” button. 
4. Turn the power off by the red knob. 
5. Turn the key and remove it, place it in the drawer. 
6. Turn off the water. 
Thermometer: 
DualLogR thermocouple thermometer with a TEF-30-T thermocouple. 
The thermocouple should never touch the coil. The thermometer itself should be 
place as far away from the inductive heating machine as possible. 
Trouble Shooting: 
Machine does not pass self-checking 
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Check cooling water flow. Try restart the machine by strictly following 
the "Shut it down" and "turn it on" procedures. 
 
On-campus limited support 
Chemistry department Electronics Shop 
 
Manufacturer support 
DAVE BRINCKERHOFF 
MSI AUTOMATION, INC. 
4065 N. WOODLAWN BLDG. #4 
WICHITA, KANSAS USA 67220 
TEL: 316-681-3566 
FAX: 316-681-1433 
CELL: 316-209-8800 
DAVE@MSIAUTOMATION.COM 
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